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Abstract 
Glucose is the predominant energy source for the brain. Due to its hydrophilic 
nature glucose cannot cross tissue membranes by simple diffusion. Glucose transporter 
type 1 (Glutl) facilitates glucose transport across the blood brain barrier (BBB). 
Haploinsufficiency of the GLUTl gene may result in developmental encephalopathy 
with seizures, as des ;ribed in the Glutl deficiency syndrome (GlutlDS). This project 
tested two hypotheses: 1) the newly suspected GlutlDS case is associated with a loss of 
function GLUTl mutation, and 2) the human GLUTl -2726 promoter fragment cloned 
is functionally active and possess transcription regulatory elements. The objectives of 
my project are: 1) to identify GLUTl mutation in a suspected GlutlDS patient, 2) to 
characterize the pathogenicity of the identified mutation, and 3) to prove the functional 
activities of the seven GLUTl promoter 5'-deletion fragments (-2726, -2387, -1987,-
1587，-1187，-787 and -262) and to identify potential regulatory elements in the 
promoter region. A novel heterozygous GLUTl insertion mutation, 1034-1035Insl2, 
in exon 6 was found in the suspected GlutlDS patient. The mutation was predicted to 
encode four extra amino acid residues (QQLS) in the transmembrane segment 7 of the 
Glutl protein, which is a tandem duplication of its adjacent sequence. The mutation did 
not change glucose uptake activity into the patient's erythrocytes, however, glucose 
efflux was reduced by 40% as compared to the parental controls. Pathogenicity of the 
mutant protein expressed in CHO-Kl cell was confirmed by a 70% reduction (p<0.05) 
of glucose influx relative to its wild type counterpart. In the GLUTl promoter study, a 
5'-deletion analysis was performed and the promoter fragments were proved 
functionally active by luciferase assay in three human cell lines (293, WRL 68，HepG2). 
ii 
The -262 fragment was found the most active and is sufficient to initiate transcription. 
Potential repressor sequences were located to between -1587 and -2726 of the GLUTl 
promoter. In conclusion, the novel 1034-1035Insl2 mutation predicted to encode for 
four extra amino acids is associated with Glut IDS symptoms and impaired function of 
the Glutl protein in both erythrocyte and CHO-Kl cells. GLUTl promoter analyses 
showed that all promoter fragments were active and the luciferase assay results implied 
that the - 2 6 2 promoter fragment contains the essential elements for initiating 
transcription. Identification of novel mutations from the suspected Glut IDS patients 
promotes our understanding of the Glut! structure-function relationship. Elucidating 
the function and regulation of the human GLUTl promoter region advance our 
understanding of transcription regulation of this gene, which enables the development 
of therapeutic strategies targeting to the promoter region for the benefits of patients 
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1.1 The Role of Glucose in Biological System 
Glucose serves as a soluble and easily distributed form of chemical energy for both 
animals and plants. Energy is released from glucose in the form of ATP. Due to its 
hydrophilic nature, glucose cannot penetrate the cell membrane lipid bilayer, specific 
carrier proteins are required for glucose to cross the tissue barriers. Therefore, glucose 
transports are of fundamental importance in energy metabolism and maintaining 
glucose homeostasis in mammalian tissues. 
1.2 Glucose Transporter Families 
Glucose transporters are classified based on their sequence homology of amino 
acids. Within each family, the members are numbered according to the chronological 
order of discovery (Wright, 2001; Joost and Thorens, 2001b). Glucose enters 
mammalian cells via 2 distinct families of cellular transporters: 1) Na+-dependent 
glucose transporters, and 2) the facilitative glucose transporters. 
For consistency, capital letters are used to abbreviate the gene name, e.g. GLUTl, 
and only the first letter of the abbreviation is capitalized when referring to the protein, 
e.g. Glutl (Joost etai , 2002). 
1 
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1.2.1 Na+-Dependt nt Glucose Transporters 
Na+-dependent glucose transporters are also known as active cotranporters or 
symporters, are energized by H+ or Na+ gradient maintained by the Na+/K+ ATPase, to 
drive glucose transport against their concentration gradients (gene symbol SLC5A, 
protein symbol Sglt) (Wright, 2001). Secondary sequence analyses suggested that they 
have 14 transmembrane a-helices (De Vivo et al., 2002b). This form of glucose 
transporter expresses on the luminal membrane of cells lining the small intestine and the 
proximal tubules of the kidney. At least three, and up to six, Sglts have been identified: 
Sgltl-Sglt6 (Hediger et al., 1987; Kong et al,, 1993; Mackenzie et al., 1994). These 
active transporters are responsible for the efficient absorption of glucose from the 
intestinal tract thus to minimize urinary loss of glucose. 
The first of this type of glucose transporter protein to be cloned was Sgltl, the 
high affinity transporter from rabbit intestine (Hediger et al, 1987). Sgltl is found 
essentially on the apical membranes of small intestinal absorptive cells and renal 
proximal straight tubules. The second Na+-dependent glucose transporter identified, 
Sglt2 appears to be ubiquitously expressed in human tissues and is predominantly 
expressed on the apical membrane of renal convoluted proximal tubules to facilitate the 
reabsorption of plasma glucose from the glomerular filtrate (Wells et al, 1992; Kanai et 
al., 1994; Zhou et al., 2003). Instead of acting as a glucose transporter, Sglt3 is found 
to serve as a glucose sensor in the plasma membrane of cholinergic neurons, skeletal 
muscle, and other tissues (Diez-Sampedro et al., 2003). Recently, it is reported that 
Sglt4 is a low affinity-type transporter mainly expressed in the small intestine and 
kidney (Tazawa et al., 2005). Sglt5 and Sglt6, and additional members of the Sglt-like 
2 
transporters are currently under investigation (Wright, 2001) and await complete 
functional and structural characterization. 
1.2.2 Facilitative Glucose Transporters 
Facilitative glucose transporters (gene symbol SLC2A, protein symbol Glut) 
(Joost and Thorens, 2001b) transport glucose into mammalian cells along a 
concentration gradient. 
The Glut family is functionally and genetically distinct from the Sglt family. To 
date, 14 Glut family members have been identified and they facilitate the bidirectional 
movement of simple sugars, down the concentration gradient across plasma or 
microsomal membnii�e in an energy independent manner via a stero-specific and 
saturable mechanism (Wright, 1993; Scheepers et al., 2004). 
Each Glut protein is genetically unique and with distinct substrate specificity, 
transport kinetics, and tissue distribution. In 2001, a new system of nomenclature of the 
GLUT/SLC2A family of sugar/polyol transport facilitators was approved by the Human 
Genome Organization Gene Nomenclature Committee and is summarized in Table 1.1 
(Joost et al, 20()la). 
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Table 1.1 Summary of the extended Glut family 
Protein Alias Gene Name Chromosome Expression 
Localization 
G l u t r —运 万[而 一...ip35:3i3 Erythrocytes, 
brain (vascular) 
Glut2^ SLC2A2/ GLUT2 3q26.2-27 Liver, islets 
Gluts'' SLC2A3/ GLUT3 13pl3.3 Brain (neuronal) 
Glut4^ SLC2A4/ GLUT4 17pl3 Muscle, fat, heart 
Gluts'' SLC2A5/ GLUTS lp36.2 Intestine, testis, 
kidney 
Glut6 …7 Glut9' SLC2A6/ GLUT6 9q34 Spleen, 
leukocytes 
Glut7^ SLC2A7/ GLUT7 lp36.2 Small intestine, 
colon 
Glut89’� Glu tXl" SLC2A8/ GLUTS 9 Testis, 
blastocyte, brain 
Glut9i2 GlutXi3 SLC2A9/ GLUT9 4pl5.3-16 Liver, kidney 
Glutl0i4 SLC2A10/ GLUTIO 20ql2-13.1 Liver, pancreas 
Glutll '- ' Glutl0i6 SLC2A11/ GLUTl 1 22q l l .2 Heart, muscle 
Glutl2 Gluts'^ SLC2A12/ GLUT12 6q23.2 Heart, prostate 
HMIT'^ SLC2A13/ GLUT13 Ambiguous Brain 
Glutl4i9 SLC2A14/GLUT14 Testis 
'Muecklcr et al., 1985; ^ukumoto et ai, 1989; 'Kayano et aL, 1988; ^Fukumoto et al., 1988b; 'Kayano 
et al., 1990; 'Doege et al., 20()0a; ^Joosl et al., 2001a; "Li et aL, 2004; 'Doege et al., 2000b; 
"'Carayannopoulos et aL, 2000; "ibberson et al., 2000; '"Phay et al., 2000; '^artaglia and Weng et al., 
1999; "McVie-Wylie et al” 2001; ''Doegc et al., 2001a; '^'Doegc et aL, 2000b;丨？Rogers et aL, 1998; 
'«Uldry et al” 2001; "Scheepers et al., 2004. 
Based on the sequence homology, the Glut family can be grouped into 3 classes (I, 
II and III). Class I comprises of the thoroughly studied glucose transporters Glutl to 
Glut4，which can be distinguished mainly by their high affinity towards glucose, distinct 
tissue distribution, and hormonal regulation, e.g. insulin sensitivity of subcellular 
localization of Glut4. The glutamine in helix 5 (QL motifs corresponding with Q161 in 
Glutl; Mueckler et al, 1994) and the STSIF-motif in the extracellular domain 7 (Doege 
et al., 1998) are specific features of class I transporters (Fig. 1.1). Class II includes 
fructose-specific transporter GlutS and three related proteins, Glut?, Glut9 and Glutl 1. 
4 
These transporters lack the tryptophan following the conserved GPXXXP motif in helix 
10 corresponding with tryptophan 338 in Glutl (Garcia et al., 1992; Schurmann et al, 
1993). Class III is comprised of five isotypes, Glut6, GlutS, GlutlO, Glutl2 and HMITl. 
The class III transporters are characterized by a glycosylation site at loop 9 and a 
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Figure 1.1 Schematic model of class I and class III Glut proteins with their 
predicted 12 transmembrane helices. Residues that are highly conserved among all 
Glut members are highlighted on a white background; residues that are considered 
characteristic for the respective class are shown in black background. (Adapted from 
Joost and Thorens, 2001b) 
Although this family is named "glucose transporter", some members of facilitative 
glucose transporters transport sugars or polyols other than glucose, for instance, GlutS 
transports fructose while HVmyoinositol cotransporter (HMITl) transports myoinositol. 
5 
Structural and functional characteristics of the individual Glut members are at varying 
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Figure 1.2 Dendrogram of multiple alignment of all members of the extended Glut 
family. Branch lengths reflect the degree of difference between the sequences. 
(Adapted from Joost and Thorens, 2001b) 
6 
1.3 Glucose Transporter Type 1 
The existence of facilitative glucose transporters in the erythrocyte membrane 
was first proposed by Widdas (1952). Since then, the erythrocytes glucose transporter 
has been an important model for studying the properties of mammalian facilitative 
glucose carrier (Carruthers, 1990). The glucose transporter cDNA clone was first 
isolated from human HepG2 hepatoma cells in 1985 (Mueckler et ai, 1985), a protein 
now called Glutl. 
1.3.1 Primary Structure of the Glutl Protein 
The genomic sequence of GLUTl is approximately 35 kb, which consists of 10 
exons and 9 introns (Fukumoto et al., 1988a). In human, the gene is mapped at 
chromosome lp35-31.3 by in situ hybridization and by southern blol analysis of the 
somatic cell hybrids (Shows et al., 1987). The GLUTl mRNA is a single transcribed 
product of 2.8 kb in length that encodes a protein containing 492 amino acids (Mueckler 
et al., 1985). 
Hydrophobic residues occupy about 60% of the Glutl protein, which is 
consistent with a transmembrane protein. Based on the deduced amino acid sequence, 
the hydropathy plot revealed the presence of 12 distinct hydrophobic segments of 
sufficient length to span the lipid bilayer, with both N- and C- termini within the cytosol 
(Mueckler et al., 1985). A single N-glycosylation site is located at asparagine-45 at the 
first extracellular loop connecting transmembrane domain (TMD) 1 and 2. The 
carbohydrates attached vary in quantity and are with distinct molecular sizes of 45-55 
kDa，which can be distinguished by electrophoresis on SDS gel. The biological 
significance of different glycosylation is still unclear (Maher et al., 1994) but N-
7 
glycosylation is believed to be related to protein stability and targeting (Asano et ai, 
1991; Asano et al., 1993). 
1.3.2 Secondary Structure 
The prediction that Glutl contains a significant amount of a-helical character 
has been supported by spectroscopic studies of Glutl purified from erythrocyte 
membranes and reconstituted into liposomes. Polarized fourier transform infrared 
spectroscopy on Glutl reconstituted into oriented multilamellar lipid films established 
that the 12 transmembrane spanning a-helices are arranged nearly perpendicular to the 
membrane, with less than 38° tilt (Chin et al., 1986). Signals corresponding to random 
coil and P-sheet structures are also detected in smaller amounts. 
1.3.3 Tertiary Structure 
The precise structure of the Glutl protein is not known. The crystallization of 
Glutl is a big challenge for researches since it probably occurs in a mixed oligomeric 
state (Hebert and Carruthers, 1991) and has a great tendency to aggregate irreversibly 
(Lundahl et al., 1991). Despite no actual crystal is available, several molecular models 
for Glutl tertiary structure have been proposed. 
Based upon the observation that the different Gluts share several conserved 
motifs, which are present in both N- and C-termini of the protein, it has been suggested 
that the mammalian transporters may have evolved from an internal duplication event of 
an ancestral 6-helix u-ansporter (Maiden et al., 1987). The constraints imposed by the 
short loops connecting the putative transmembrane segments are unlikely to be a single 
8 
group of 12 helices. By low resolution electron microscopic analysis, it is suggested 
that the 6 helices in the C- and N-termini may comprise two separate but closely packed 
groups to produce a bilobular structure which is structurally related to the Escherichia 
coli {E. coli) lactose permease (Li and Tooth, 1987). 
Moreover with the absence of any crystal structure data, most information about 
structure/function relationships of Glutl has been obtained through affinity labeling and 
site-directed mutagenesis experiments. Several regions of the Glutl structure that 
participate in glucose binding have been identified using photoactivatable inhibitors 
known to interact with specificity to either cytoplasmic or exofacial surfaces of the 
transporter. Cytochalasin B (Cyt B), a fungal metabolite, is the most intensively studied 
(Shanahan, 1982). Kinetic studies showed that Cyt B is a competitive inhibitor of Glutl, 
in the cytoplasmic surface of the transporter (Basketter and Widdas, 1978). Cyt B 
binding site has been mapped to the cytoplasmic regions of transmembrane segment 10 
and 11 (Holman and Rees, 1987). 
Several exofacial-specific photoaffinity reagents that contain a membrane 
impermeable bis-ma innose core structure have been developed (Koumanov et ai, 
1998). Among all, 2-N-[4-(r-azitrifluoroethyl)benzoyl]-l,3-bis-(D-mannos-4-yloxy)-
2-propylamine (ATB-BMPA) is one of the most extensively used (Clark and Holman, 
1990). ATB-BMPA binding site has been mapped to helix 8 (Saravolac et al., 1996). 
ATB-BMPA binding is observed when both N- and C- domains are co-expressed, 
indicating that these two domains can assemble to form a stable complex even though 
they are not functionally essential (Cope et al., 1994). 
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The extensive cysteine-scanning mutagenesis in conjunction with p-
chloromercurybenzenesulfonate (pCMBS) modification has also provided experimental 
evidence for the solvent accessibility of several TMD residues. In this analysis, all the 
native cysteine residues of Glutl molecule were first changed into either glycine or 
serine, leading to a functional cysteine-less (C-less) Glutl. This C-less Glutl was used 
to produce a series of mutants in which each amino acid was individually changed to 
cysteine, and resultant mutants were expressed in Xenopus oocytes. The glucose 
transport activities of the mutants were then determined with the addition of pCMBS. If 
the glucose transport activity was altered after pCMBS treatment, the original amino 
acid residue was thought to be exposed to the external solvent, since pCMBS is a 
membrane impermeaMe thiol-specific reagent that binds to cysteine residue (Mueckler 
and Makepeace, 1999). By cysteine-scanning mutagenesis helices 1 (Heinze et al., 
2004)，2 (Olsowski et al., 2000), 5 (Mueckler and Makepeace, 1999), 7 (Olsowski et al； 
2000; Hruz and Mueckler, 1999), 8 (Mueckler and Makepeace, 2004), 10 (Mueckler 
and Makepeace, 2002) and 11 (Hruz and Mueckler, 2000) were found participating in 
the formation of glucose transverse passage. 
In 2001, Zuniga (Zuniga et al., 2001) and his group described a three-
dimensional structure, of Glutl based on helical packing schemes proposed for Glutl 
and further refined using energy minimization, molecular dynamic simulations, and 
quality and environmental scores. Their model is consistent with other mutagenesis and 
biochemical studies. 
In consideration of the present studies on the helix packing of Glutl, different 
proposed model is obtained with similar arrangement. Since helix 7 appears to be the 
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most sensitive to cysteine mutagenesis, pCMBS sensitivity was found along a majority 
of the circumference of the helix, suggesting that this TMD is more centrally positioned 
within the aqueous channel. However, confirmation of the models will definitely 
require more direct determinations of inter-helical distances such as those obtained for 
the E. coli lactose permease (Kaback et al, 1997). 
Figure 1.3 Proposed model for Glutl helix packing. Schematic representation of a 
potential arrangement of the 12 transmembrane a-helices in Glutl. A) Transmembrane 
helices known to contain solvent accessible residues are shaded. The water filled 
channel is depicted by the dotted area (Adapted from Hruz and Mueckler, 2001). B) 
Arrangement of the TMDs after energy minimization (Modified of Zeng et aL, 1996). 
1.3.4 Kinetics Properties 
Before the cloning and sequencing of GLUTl gene, the proposed functional 
mechanism of glucose transport of the protein was based on the detailed kinetic analysis 
(Lowe, 1989; Carruthers, 1990). These studies support an alternating conformational 
model for facilitative transport (Gorga and Lienhard 1981; Lowe 1989). According to 
this model glucose ^inds at a single centrally located site in Glutl that isomerizes 
between inward and outward facing conformation. The altered direction of ligand 
dissociation from the site mediates the transport. Furthermore, the kinetics behavior of 
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the transporter within the erythrocyte membrane suggests a physiologically relevant 
function for dimer and/or tetramer formation (Hebert and Carruthers, 1992) and the 
homotetramer with cooperative interaction between two Glutl dimers. Within each 
dimer, one subunit has its exofacial site exposed while the other has its cytoplasmic 
sugar binding site accessible. This model satisfactorily accounts for most of the kinetic 
data. However, an alternative model for glucose transport is proposed suggesting that 
hexoses diffuse between recognition sites in the transport pathway independently of 
protein conformational changes (Cunningham et al； 2006). This multisite model 
accounts for saturation and inhibition kinetics and relaxes the requirement for uniform 
maximal rates of hexoses transport (Naftalin et al., 2002). 
1.3.5 Tissue Distribution 
Glutl expresses at different levels in almost every tissue. Its ubiquitous 
expression is important in maintaining basal glucose uptake for metabolism and its 
expression usually correlates with the rates of cellular glucose metabolism (Bell et al., 
1993; Gould and Holman, 1993; Uldry and Thorens, 2004). The expression of Glutl is 
the highest in the placenta (Fukumoto et al., 1988a) while a significant amount of Glutl 
is also expressed in erythrocytes, fibroblast, blood tissue barrier and astrocytes (Brown, 
2000). Glutl has also been shown to be highly expressed in cancer cells like colon 
carcinoma and hepatoma (Fukumoto et al., 1988a). 
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1.3.6 Multifunctional Property 
Recent reports indicated that Glutl is a multifunctional transporter. Apart from 
glucose transport, it has been found to recognize other substrates such as the oxidized 
form of vitamin C (dehydroascorbic acid) (Vera et al., 1993; Rumsey et al” 1997; Agus 
et al., 1997), D-mannose (Gould et al., 1991; Colville et al., 1993), water (Fischbarg et 
al., 1990), galactose (Takakura et al., 1991), glycopeptides (Polt et al； 1994), and 
glucosamine (Uldry et al., 2002). 
1.3.7 Characterization of GLUTl Gene 
The sequence of the human promoter region and the site of transcription 
initiation was first cloned and characterized in 1988 (Fukumoto et al., 1988a). The 
promoter region contained several different types of transcriptional control elements 
(Fukumoto et al., 1988a), including a TATA box, two binding sites for the transcription 
factor Spl (Dynan and Tjian, 1985), a CCAAT box, a potential AP2-binding site 
(Imagawa et al., 1987), two GC boxes (Kadonaga et al., 1987) and a sequence that is 
found in the promoter region of several phorbol ester [tetradecanoylphotbol acetate 
(TPA)]-inducible genes, which functions as TPA-inducible enhancer/TPA-responsive 
element (TRE) (Angei et al., 1987). 
Two enhancer elements were identified in the mouse GLUTl gene. The first 
one, enhancer-1, is located at 2.7 kb upstream of the cap site of the gene and contains 
the homologous sequences with 2 TREs, a SRE, a cyclic AMP-responsive element 
(CRE) and 3 GC boxes. The second one, enhancer-2, is located within the second 
intron between 16.7 to 18.0 kb downstream from the transcription initiation site and 
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contains the homologous sequences with 2 TREs and one CRE (Murakami et al., 1992; 
Treisman, 1986). These enhancer elements appear to be responsible for serum-induced 
GLUTl expression. Similar enhancers were identified in the human GLUTl gene. The 
putative enhancer-1 iv found at -3.6 kb upstream of exon 1 while the putative enhancer-
2 is similar to the mouse enhancer-2 as it is also located in intron 2 of human GLUTl 
gene (Ng et al,, 2002). 
1.3.8 Regulation of GLUTl Expression 
The expression of GLUTl expression is strictly regulated. Previous studies 
showed that GLUTl gene is responsive to serum, growth factors, stress and oncogene 
transformation. 
The addition of serum and polypeptide growth factors such as PDGF，FGF, and 
EGF in quiescent fibroblasts increases GLUTl mRNA levels by a rapid and transient 
activation of the gene (Hiraki et al” 1988; Hiraki et al., 1989). The gene responses to 
the stimuli directly and in a protein synthesis-independent manner and is also 
dissociable from mitogenesis (Hiraki et al., 1988). Thus, GLUTl gene is one of the so-
called "immediate early genes". 
The expression of GLUTl is regulated mainly at the post-transcriptional level in 
a variety of pathophysiological conditions, including glucose deprivation, hypoxia 
(Boado and Pardridgf, 1993; Stein et al., 1995; Levy et al； 1996) and hyperosmolarity 
(Hwang and Ismail-Beigi, 2006). Studies showed that GLUTl mRNA and transporter 
expression were markedly up-regulated in response to hypoxia (Bashan et al., 1992; 
Loike et al., 1992; Ismail-Beigi, 1993). The mechanism of hypoxia-induced gene 
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expression of GLUTl has been investigated in cell culture models and there is evidence 
showing the up-regulation of GLUTl gene in hypoxia is mediated by both 
transcriptional and post-transcriptional mechanisms (Stein et al” 1995; Levy et al., 
1996; Behrooz and Ismail-Beigi, 1997). The presence of the Spl site in the GLUTl 
promoter was found to be essential for the positive response of the promoter to 
hyperosmolarity (Hw mg and Ismail-Beigi, 2006). 
Hexose concentration also plays a role in the regulation of GLUTl gene. In the 
absence of other factors like hormones, hexose concentration above the normal range 
down-regulates the GLUTl mRNA level or vice versa (Walker et al., 1988; Walker et 
al” 1989). Therefore, it is proposed that Glutl belongs to the glucose-regulated protein 
family of stress proteins and its ubiquitous expression may serve a specific purpose 
during cellular stress (Wertheimer et al., 1991). 
Beside normal cells, Glutl protein is always found in tumor cells. It is because 
tumor cells are metabolically active suggests that there is a high consumption of glucose 
and it has been shown that the rate of glucose uptake in tumor cells is higher than that of 
normal cells (Hatanaka, 1974). Oncogene products such as abl, v-src and ras, can 
stimulate GLUTl gene transcription by targeting the promoter and the two enhancers 
(Birnbaum et al., 1987; Flier et al., 1987; Hiraki et al., 1989; Murakami et al., 1992). 
The increase in glucose uptake upon oncogenic transformation is one of the earliest 
known effects of oncogenesis on the expression of a gene encoding a protein of well-
defined function. 
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1.4 Glucose Transporter Type 1 and the Brain 
In the resting state, adults use about 20% of whole-body glucose for brain 
metabolism (Cremer, 1982; Clarke and Sokoloff, 1994) and in children the brain 
glucose demand is even higher as it compresses to 80% of whole-body glucose 
utilization (Cremer, 1982; Robinson, 2001). D-glucose is the predominant fuel for 
brain metabolism and the combustion of blood borne glucose provides over 98% of 
energy for sustaining neuronal function of the brain (Pardridge and Boado, 1993). The 
ability of the brain t(, use alternative fuels is very limited as apart from glucose it can 
only metabolize ketone bodies but not fat under fasting condition (Clarke and Sokoloff, 
1994). 
Glucose transport across the blood brain barrier (BBB) is a multistep process 
involving glucose import at luminal membrane and glucose export at the abluminal 
membrane of the capillary endothelial cell, glucose diffusion into brain parynchema, 
and glucose uptake into brain cells (Fig. 1.4). Glutl is selectively expressed at high 
level in the endothelial cells of the microvasculature of the brain and is responsible for 
transfer of glucose across the BBB (Pardridge et al., 1990). In these cells, Glutl is 
predominantly present as the 55 kDa glycoform. It is becoming apparent that the 
delivery of glucose to neurons is, at least in part; mediated by astrocytes (Gerhart et al., 
1989) and these cells also express Glutl but mainly as the 45 kDa glycoform (McCall et 
al., 1996). The uptake of glucose into the neurons to support their energy metabolism is 
mediated by Glut3 (Duelli and Kuschinsky, 2001). 
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CAPILLARY ASTROCYTE NEURON 
Figure 1.4 Location of different glucose transporters in the brain. Glutl is 
abundant in its 55 kDa glycoform in the endothelial cells, while the 45 kDa glycoform 
is expressed in astrocytes. Glut3 is the neuronal glucose transporter. (Adapted from 
Duelli and Kuschinsky, 2001). 
In normal condition, the capacity of hexokinase for glucose is considerably 
greater than the capacity of the glucose transport system in order to maintain a constant 
concentration gradient across the BBB. Glucose therefore moves transcellularly down 
its gradient from 5 mM in blood to about 2-3 mM in the brain extracellular fluid 
(Pardridge and Boado, 1993). 
The transport of glucose across the BBB by Glutl is often the rate-limiting step 
to the subsequent metabolism in peripheral cells, which is the first step in supplying 
glucose to the brain. Under normal physiological condition, the balance between the 
supply and demand is maintained and sufficient glucose is available to fuel neuronal 
function. However, if the balance is disturbed, it may cause serious problems. Glucose 
deficiency can result in compromised brain functions, ranging from mild confusion to 
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life-threatening seizure, loss of consciousness, coma and even death (Pardridge and 
Boado，1993; Willemsen et al., 2003). 
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1.5 Glucose Transporter Type 1 Deficiency Syndrome (GlutlDS) 
1.5.1 Background of GlutlDS 
Glucose transporters play the key role in providing metabolic energy and 
building blocks for the synthesis of biomolecules. Dysfunciton of these transporters 
have been associated with a variety of human diseases including the familial glucose-
gal actose malabsorption (SGLTl), renal glycosuria (SGLT2), glucose transporter type 1 
deficiency syndrome (GLUTl) and non-insulin dependent diabetes mellitus (GLUT4) 
(Brown, 2000). 
GlutlDS (OMIM 606777) is the first example of a genetic disturbance of 
substrate transport across the BBB (De Vivo et al., 2002a). The first patient was 
evaluated for infantile-onset seizures since 2 1/2 months, followed by delays in early 
neurological development (De Vivo et al., 1991). A consistently low cerebrospinal 
fluid (CSF) glucose (hypoglycorrhachia) on consecutive lumbar punctures and normal 
blood glucose concentration (normoglycemia) were observed. The findings then led De 
Vivo and colleagues to conclude that there was a defect in the glucose transport system 
from the blood across the BBB, into the brain. Further studies showed that GlutlDS is 
associated with the loss of function mutation of GLUTl gene due to an autosomal 
dominant mechanism of transmission, thus all identified patients are haploinsufficient 
(Brockmann et al., 1999; Wang et al., 2000; Brockmann et al, 2001; Ho et al, 200la; 
Klepper et al., 2001b). Both sporadic and familial cases have been identified that the 
defective Glutl impairs glucose transport across the BBB, which results in energy 
deficiency and metabolic defects (De Vivo et al., 2002a). 
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Since the diagnosis of the first GlutlDS patient, approximately 100 patients 
have been identified clinically (Leary et al., 2003; Pascual et al., 2004; Ito et al., 2005). 
Molecular analyses of GLUTl gene in affected individuals have revealed heterozygous 
and hemizygous mutations including missense, nonsense, splice site，insertion, or 
deletion mutations. So far，the mutations found in the majority of patients are missense 
mutations as listed in Table 1.2 and Fig. 1.5. Homozygous mutation has not been found 
as it is believed to result in embryonic lethality, which has been confirmed in the 
GlutlDS mouse model (Wang et al., 2006). 
. « 
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Table 1.2 Summary of mutations found in GlutlDS patients 
Number of Nucleotide change Location Amino acid Mutation Type 
patients change 
1 280A>T Exon 2 N34f — 
— 1 280A>G Exon 2 N34S'' 
1 3 7 6 ^ Exon 3 S66F' 
“ 3 272G>A Exon 3 G91D' 
1 )56G>T Exon 4 R126L' 
3 556G>A Exon 4 R126H' 
— 2 555C>T Exon 4 R126C' 
1 567G>A Exon 4 G13QS" . 
1 615G>A Exon 4 E146K' Missense 
— 1 636C>T Exon 4 R153C'-
1 920G>C Exon 6 E247D"' — 
1 945A>G, Exon 6 K256V' 
945A>T 
_ 2 1 0 6 3 0 T Exon 7 T295M"''-
“ 1 1108C>T Exon 7 T310I"' 
3 1 1 7 6 0 G Exon 8 R333W^''-
1 1 1 7 6 0 T 
1 1167C>T Exon 8 R330X^ 
1 1368C>T Exon 9 Q379X'- — Nonsense 
“ 1 1526C>A Exon 10 Y449X-^ — 
1 ]"545A>T Exon 10 K456X' 
1 368-369Ins23 Exon 3 FS>Stop^ — 
“ 1 741-742InsC Exon5 FS>Stop^ — 
1 888-889InsG Exon 6 FS>Stop^ Insertion 
1 1540-1541Insl4 Exon 10 FS^ 
1 1562-1563Ins4 Exon 10 FS>Stop" 
1 266delC, Exon 2 FS>Stop4 
267A>T 
1 516-517insTTGAG, Exon 4 FS>Stop'^ 
517-531dell5 
2 684-686delCTC Exon 4 L e u l 6 9 d e F ~ 
1 904delA Exon 6 FS>Stop'* 
1 969delC Exon 6 FS>Stop'- Deletion 
1 969delC, 971C>T Exon 6 FS>Stop'-
1 1086delG Exon 7 FS>Stop^ 
— 1 1159-116QdelTG Exon 8 FS>Stop"^ 
i 1395- Exon 9 FS>Stop'-
139i>>delGTTGC 
1 1377delC Exon 9 FS>Stop'-
1 197+1G>A, Intron 1 4 
i 857T>G Intron 5 ^ 
858G>A, Splice site 
858+ldellO 
1 1151 + 1G>T Intron 7 : 
3 Large scale deletion 4”*s Hemizygosity 
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Mutation nomenclature is based on the guideline described by Antonarakis (1998). Nucleotide and amino 
acid positions are according to the publish sequence (Mueckler et al., 1985). 
®X specifies a termination codon 
bps specifies a frame shift 
'Klepper et al., 1999c; ^Klepper et al., 2001b; ^Brockmann et al, 2001; Vang et al., 2000; ^Seidner et al, 
1998; ^Lange et al, 2003; 'Overweg-Plandsoen et al, 2003; ®Ho et al, 2001a; ^Wang et al., 2001; 
Vivo et al, 2002b; "Pascual et al, 2004; '^ Wang et al, 2005 
A) B) 
.少 1 5 6 2 - 1 5 6 3 i n s A T C G R126L, R126H, R126C 
S J ^ Y � 『 • • N ^ ^ T T C � N 3 4 I , N 3 4 S S 6 6 F 7 T 2 9 5 M 
. O l i g o s a c c h a r i d e / / / / y T 3 l O I 
"101 •_io86.io87deiG o cw ^ r f n t n ^ ^ 
i f ^ i l l C ™ , 污丄 El丄 / C j N a a v ( ^ c � � r 
G9 515-529deICGAAACTGGGCAAGT \ ^ ^ ^ ^ CUUJfc S66F c a r — • 368-369ins rrO/l'7n 
• TCCTGCCCACCACGCTCACCACC ' U 
N34I ——266-267delC,267A>T N34S Z I 
X 197+lg>a 
T 
Figure 1.5 Summary of mutations found in GlutlDS patients. A) Diagram showing 
the position of known GlutlDS-assosiated mutations on the GLUTl gene (Adapted 
from Wang et al, 2005). B) Glutl protein structure with known missense mutations 
indicated. 
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1.5.2 Clinical Features of GlutlDS 
In general, the clinical features are heterogenous and often non-specific. In the 
majority of patients, <hey are normal at the delivery and neonatal period but develop 
seizures during infancy and early childhood with varied frequency and character. As 
more patients are identified, three clinical phenotypes have emerged (De Vivo et al., 
2003). The first phenotype (classic) is a developmental encephalopathy with seizures. 
Seizures become more synchronized with brain maturation and are presented clinically 
as generalized events associated with classic 2.5- to 4-Hz spike-wave discharges 
electrically (Leary et al., 2003). The clinical seizures do not respond to or are even 
worsened with the use of antiepileptic drugs, such as phenobarbital, and respond rapidly 
to a ketogenic diet (\V^ang et al” 2005). The infantile-onset epileptic encephalopathy 
also associates with delayed neurological development, deceleration of head growth and 
abnormalities of movement or posture including myoclonus and dystonia. The intensity 
of the neurological symptoms fluctuates unpredictably and is influenced by 
environmental factors such as fasting or fatigue. Other symptoms include speech and 
language impairment and cognitive impairment ranging from learning disabilities to 
severe mental retardation. 
The second phenotype identified recently (Overweg-Plandsoen et al., 2003) is 
characterized by mental retardation, dysarthric speech, and intermittent ataxia but 
without any clinical seizures and the third phenotype is characterized by choreoathetosis 
and dystonia and with no seizures (Friedman et al., 2002). These non-classic 
phenotypes, which represent about 15% to 20% of the GlutlDS patient population, 
indicate the importance of GlutlDS diagnostic studies in children with unexplained 
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neurological symptoms including mental retardation and movement disorders (De Vivo 
et al., 2003). 
The current understanding of glucose transport in the brain may provide an 
explanation for these features. Cerebral metabolic rate for glucose is low during fetal 
development and metabolic rate increases by the time of birth and continues for the first 
decade of life, and gradually recedes during the second decade of life to values seen in 
early adulthood (Chugani et al., 1987). Therefore patients with GlutlDS face 
increasing vulnerability of brain damages over time. 
Biochemical signatures of GlutlDS include unexplained hypoglycorrhachia 
accompanied by normoglycemia (De Vivo et al., 1995) and a low to normal 
corresponding CSF lactate value, reflecting the decreased availability of glucose for 
cerebral glycolysis although the intracellular pathways for glucose utilization remain 
intact (Overweg-Plandsoen et al., 2003). The CSF/blood glucose ratio in GlutlDS 
patient when measured in a postabsorptive preprandial state is consistently 50% lower 
than normal control value. Normally, the ratio is approximately 0.65，whereas in 
patient the ratio is 0.33 (De Vivo et al., 1995). Expression of Glutl in patient 
erythrocyte membranes has found to be either normal or reduced by approximately 50% 
in some cases (Seidner et al, 1998; Klepper et al” 1999c). 
1.5.3 Genotype-Phenotype Correlations 
The phenotypes of GlutlDS patients vary from minimal phenotype, in which the 
Glutl associated with missense mutation retains 75 to 100% (hypothetical value) 
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function, to severe phenotype where only 25 to 50% residual function of Glutl is 
preserved (Wang et al., 2001). 
100% 
Phenot>^^^^ — 0% 
Minimal Mild Moderate (Classic) Severe Embryonic 
lethal 
Missense Missense Hemizygosity, Compound 
Nonsense, Deletion, heterozygosity Homozygous 
Insertion, Splice site mutation 
‘ 
100% 
Figure 1.6 Phenotype-genotype correlations in GIutlDS. (Modified from Wang et al., 
2005) 
Homozygous mutation of the GLUTl gene is hypothesized to be embryonially 
lethal due to the lack of glucose supply to support the development of the embryo, since 
Glutl is the major glucose transporter expressed on the plasma membrane of 
syncytiotrophoblast and cytotrophoblast at the embryonic stage (Takata and Hirano, 
1997). Recently, embryonic lethality has been confirmed in homozygous GLUTl " 
mice (Wang et al” 2006). 
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1.5.4 Diagnosis 
The diagnosis" of GlutlDS is established in neurologically impaired patients 
including: reduced CSF glucose concentration, low CSF/blood glucose ratio, the 
demonstration of impaired glucose uptake activity of Glutl in erythrocytes and the 
mutational analysis of the GLUTl gene. 
Clinical features such as hypoglycorrhachia is a distinctive observation in 
GlutlDS patients. In these patients, the absolute CSF glucose concentration seldom, if 
ever, exceeds 40 mg/dL (De Vivo et aL, 1995). Any functional defect of Glutl protein 
is tested using erythrocytes. Since Glutl expressed in erythrocyte membranes is 
immunologically and chemically indistinguishable from the Glutl isoform expressed at 
the BBB (Kalaria et al., 1988), thus making erythrocyte a screening model for glucose 
uptake study. A decreased 3-0-methyl-D-glucose uptake in erythrocyte supports the 
diagnosis of GlutlDS. Patients with GlutlDS have a reduction of about 50% in glucose 
uptake compared to the normal control (Klepper et al., 1999b). Apart from functional 
testing of the Glutl protein, genomic DNA extracted from white blood cells or cultured 
skin fibroblasts of the potential GlutlDS patients is used as a template for PGR 
amplification with pfimers specific to each of the exon-intron boundaries of human 
GLUTl gene (Klepper et al” 1999c). PGR products are then subjected to sequence 
analysis to identify mutations. 
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1.5.5 Management 
1.5.5.1 Ketogenic Diet 
The ketogenic diet was introduced as a treatment for GlutlDS in 1991 (De Vivo 
et al., 1991) before ！he confirmation of a decrease in glucose transport across tissue 
membrane. In the diet, most carbohydrates are substituted by lipid and proteins in 
varied ratios, i.e. it is a high-fat, low-carbohydrate, low protein diet with restricted 
vitamin and fluid intake. 
Ketone bodies bypass the Glutl defect and enter the brain by a monocarboxylic 
acid transporter thus providing an alternative energy source for the brain (De Vivo et al” 
1991). The brain normally prefers glucose as the fuel, but under glucose deficient state 
the brain can adapt to use ketone bodies like acetoacetate or D-p-hydroxybutyrate 
(Owen et al” 1967). 
The ketogenic diet is highly effective in controlling the seizure (Leary et al., 
2003) while being tolerated in most GlutlDS patients. In proven cases of GlutlDS, 
ketogenic diet should be introduced as early as possible, especially during the early 
stage of physical development and brain growth. The benefit of this dietary treatment is 
less pronounced and less significant in older patients due to long standing deficiency of 
energy supply to the brain (von Moers et al., 2002). Despite the control of seizure, this 
dietary has less effcct on neurobehavioral deficits involving cognitive and social 
adaptive behavior. 
Although the ketogenic diet is effective in seizure control, some GlutlDS 
patients are still irresponsive to the diet, therefore, other strategies are attempted. Aside 
from providing alternative brain fuel sources, researchers have tried to enhance GLUTl 
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gene expression or the activity of Glutl transporter (Kulikova-Schupak et al., 2001). In 
order to enhance the expression or activity of the Glutl protein, Glutl activators are 
investigated, a-lipoic acid (thioctic acid) is a kind of antioxidant that has been shown to 
facilitate glucose transport in Glut4-dependent cultured skeletal muscle (Klip et al., 
1994). When exposing to high concentration of a-lipoic acid, similar result was 
obtained on the Glutl transport systems in vitro (De Vivo et al., 1996; Kulikova-
Schupak et al., 2001; De Vivo et al., 2002b). The patients supplemented with a-lipoic 
acid only responded modestly. It may due to the fact that the dose taken orally is 
insufficient to simulate experimental conditions (Kulikova-Schupak et al., 2001). For 
the health of the GlutlDS patients it is also important for them to avoid drugs that 
inhibit the activity of Glutl proteins. Barbiturate and phenobarbital, which are 
commonly used antiepileptic drugs in treating infantile-onset seizures. Instead of 
improving seizure control, these drugs worsen the clinical state of patients. Barbiturates 
are known to inhibit glucose transport (Honkanen et al, 1995) and in vitro evidence 
show that it will aggravate the Glutl transport defect in erythrocytes of patients with 
GlutlDS (Klepper et al., 1999a). 
Methylxanthines such as caffeine and theophylline are known to inhibit glucose 
transport and inhibit Glutl activity in erythrocytes (Ho et al., 2001b). As described in 
literature, a female patient avoided coffee because it would further impair her 
neurological functioning (Brockmann et al., 2001). Thus, GlutlDS patients are 
recommended to avoid any caffeine-containing products. 
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1.6 Hypothesis and Objectives 
Genetic variations such as mutations are often associated with diseases whereas 
single nucleotide polymorphisms in the gene may be related to the susceptibility to 
some diseases. The knowledge about the disease-associated genetic variations 
promotes better understanding of the genetic diseases and development of therapeutic 
strategy that benefits the patients. In this project the genetic variations of the GLUTl 
gene in relation to the pathogenesis of GlutlDS are of special interest, the effect of such 
variation in the gene on the function and expression of the Glutl protein are therefore 
investigated. We hypothesize: 1) the newly suspected GlutlDS case is associated with 
a loss of function GLUTl mutation, and 2) the human GLUTl -2726 promoter 
fragment cloned is functionally active and possess transcription regulatory elements. 
Hence the aim of this project is: 1) to identify GLUTl mutation in a suspected GlutlDS 
patient, 2) to characterize the pathogenicity of the identified mutation and 3) to prove 
the functional activities of the seven GLUTl 5'-deletion fragments (-2726, -2387，-1987, 
-1587, -1187，-787 and -262) and to identify potential regulatory elements in the 
promoter region. So as to elucidate the effect of GlutlDS-associated mutation on Glutl 
protein expression and function also, to facilitate the study of promoter regulation in the 
future. The main theme of the project is illustrated in the following chart: 
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Change of amino acid sequence Change of promoter length 
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Loss of function of G lu t l protein Identification of regulatory elements \ + 
\ Therapeutic implications 




Figure 1.7 Ma in thekne of my thesis. By studying the genetic variations in the coding 
region of the human G L U T l gene associated wi th G lu t lDS and the identification of 
regulatory elements in G L U T l promoter region can promote a better understanding on 
the functional consequences of the G L U T l gene variations and the development of 
therapeutic strategies that target G lu t lDS and other Glutl-associated diseases e.g. 
cancers. 
The long-term goal of the project is to promote better understanding of the effect 
of genetic variations in the G L U T l gene on G l u t l protein expression and function. 




Biochemical and Molecular Analysis of GLUTl in a 
Suspected GlutlDS Case 
GlutlDS patients generally suffer from seizure, developmental delay, and 
hypoglycorrachia (De Vivo et al” 1991; De Vivo et al., 1995). Different heterozygous 
in vivo mutations have been reported in GlutlDS patients, indicating that the disease is 
an autosomal dominant condition resulting from haploinsufficiency. Pathogenic 
mutations often result in single amino acid changes or frame shifts that cause pre-
mature transcription termination. Since the molecular weight and antigenic properties 
of erythrocyte Glutl protein is identical to the Glutl protein in brain capillary 
endothelial cells (Di ;k et la., 1984), a Glutl-deficiency state can be confirmed in a 
patient by the analysis of Glutl function, Glutl protein expression, and GLUTl 
molecular analyses using patients' blood samples. 
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2.1 Materials 
2.1.1 Clinical History of Suspected GlutlDS Patient 
The patient is a 29-year old male with mental retardation. At the age of 3 
months, he developed hic-cup seizures and was found to have communicating 
hydrocephalus. At the age of 8 months, EEG revealed epileptogenic discharges and he 
was then treated with antiepileptic drugs. At the age of 20，phenytoin was given and his 
GTC convulsion disappeared. However, he develops tremor and gait disturbance in the 
morning and when he is hungry. These symptoms disappear after eating some sweets. 
His glucose level in CSF is 38 mg/dL, while the blood glucose level is 80 mg/dL (Fujii 
et al., 2006). The cerebrospinal fluid to blood glucose level is 0.475, which is lower 
than normal -0.65 (De Vivo et al., 2002b). 
2.1.2 Blood Samples 
Blood samplrs were obtained from the suspected patient and the patient's 
parents. Blood samples were preserved in citrate-dextrose-phosphate solution, 
immediately put on ice blocks, and processed within 2 weeks. 
2.1.3 Reagents and Buffers for Reverse Transcription 
2.1.3.1 First Strand Buffer (5x) 
The first strand buffer (Amersham, GE Healthcare, Buckinghamshire, England) 
was supplied as a 5X solution containing 250 mM Tris-HCl, pH 8.3，95 mM KCl, 15 
mM MgCl2, 50 mM CTT. The buffer was stored at -20°C until use. 
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2.1.3.2 Oligo (dT)i5 
01igo(dT)]5 was purchased from Invitrogen, Life Technologies (Carlsbad, CA， 
USA) and dissolved in autoclaved double distilled water to a stock concentration of 100 
f_iM and stored at -2()°C until use. 
2.1.3.3 RNAguardTM Ribonuclease Inhibitor (Human Placenta) 
R N A g u a r d T M (Amersham, GE Healthcare, Buckinghamshire, England) is a 
noncompetitive inhibitor of ribonucleases, which functions by non-covalently binding 
to RNase A-type enzymes. The inhibitor was isolated from human placenta using 
affinity chromatography. One unit was the amount of protein required to inhibit the 
activity of 5 ng of RNase A by 50%. It was stored at -2()°C until use. 
2.1.3.4 DNA Nucleotide Mix 
DNA nucleotide mix was purchased from Promega (Madison, WI, USA) which 
is a ready-to-use premixed solution containing the sodium salts of the 4 nucleotides, 
each at a concentration of 10 mM (pH 7.5). The solution was stored at -20°C until use. 
2.1.3.5 DEPC-Treated Double Distilled Water 
Diethyl-pyrocarbonate (DEPC) (Amersham, GE Healthcare, Buckinghamshire, 
England) was added to double distilled water at 1:1000 ratio i.e. 0.1% (v/v) DEPC 
water. The DEPC-added water was then stirred vigorously overnight to disperse the 
DEPC. After that the solution was autoclaved at UVC for 20 minutes to vaporize the 
remaining DEPC. The DEPC-treated water was stored at room temperature. 
2.1.3.6 M-MLV Reverse Transcriptase 
M-MLV reverse transcriptase (Amersham, GE Healthcare, Buckinghamshire, 
England) was purified from an E. coli containing a clone of the Moloney Murine 
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Leukaemia Virus reverse transcriptase gene. One unit of enzyme incorporates 1 nmol 
of deoxynucleotides into acid-precipitable material in 10 minutes at 37 °C. The enzyme 
was stored at -20°C. 
2.1.4 Reagents and Buffers for TA Cloning 
2.1.4.1 TOPO TA Cloning® Kit 
The TOPO TA Cloning® kit was purchased from Invitrogen, Life Technologies 
(Carlsbad, CA, USA). It provides a highly efficient, one-step cloning strategy for the 
direct insertion of Tag polymerase-amplified PCR products into a plasmid vector. 
2.1.5 Reagents fo r Genomic DNA Extraction 
2.1.5.1 QIAamp DNA Blood Midi Kit 
The DNA extraction kit was purchased from Qiagen (Hilden, Germany). It 
provides rapid DNA purification method from a small amount of blood. The purified 
blood is suitable for long-range PCR amplification. 
2.1.5.2 Gel Extraction Kit 
DNA fragments from agarose gel were purified by DNA Gel Extraction Kit 
purchased from Viogene (Oberhausbergen, France). 
2.1.6 Reagents and Buffers for Polymerase Chain Reaction (PCR) 
2.1.6.1 lOX PCR Buffer 
lOX Reaction Buffer (Promega, Madison, WI, USA) was supplied as a lOX 
solution containing 200 mM Tris-HCl, pH 8.8, 100 mM KCl，100 mM (NH4)2S04，20 
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mM MgS04 and 1% Triton X-100 and 1 mg/ml nuclease-free BSA. It was stored at -
arc. 
2.1.6.2 Primer Pairs 
The oligonucleotide primers specific to each of the exon-intron boundaries of 
the published sequences of human GLUTl gene were synthesized by Invitrogen, Life 
Technologies (Carlsoad, California, USA). The lyophilized primer pairs were 
reconstituted in autoclaved double distilled water to a stock concentration of 100 |LIM 
and a working solution of 10 i^M was prepared. Both the stock and working solution 
were stored at -20°C. 
2.1.6.3 Pfu DNA Polymerase {Pyrococcus furiosus) 
Pfu DNA polymerase was purchased from Promega (Madison, WI, USA). It is 
a thermostable enzyme of approximately 92 kDa isolated from Pyrococcus furiosus. 
One unit was defined as the amount of enzyme required to catalyze the incorporation of 
10 nmol of nucleotides into acid insoluble material in 30 minutes at 75°C. 
2.1.7 Reagents and Buffers for Agarose Gel and Gel Electrophoresis 
2.1.7.1 Tris-Borate-EDTA (TBE) Electrophoresisi Buffer (5X) 
The 5X stock TBE electrophoresis buffer was prepared by dissolving 450 mM 
Tris-borate (Amersham, GE Healthcare, Buckinghamshire, England) and 10 mM EDTA 
(Sigma, St. Louis, MO, USA) in 1 L of double distilled water with pH calibrated to 8.0 
using 6 N HCL and 2 M NaOH. The working IX TBE buffer was prepared by diluting 
one part of the 5X stock buffer to 4 parts of double distilled water. Both stock and 
working solutions were stored at room temperature. 
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2.1.7.2 Agarose Gel 
DNA and RNA fragments were separated on 1% (w/v) agarose gel (Sigma, St. 
Louis, MO, USA), which was prepared by dissolving 0.4 g of agarose in 40 ml of 
IXTBE buffer followed by heating in an microwave oven. Two microliters of ethidium 
bromide were added per 40 ml of IX TBE. 
2.1.7.3 Ethidium Bromide (EtBr) 
EtBr solution (10 mg/ml) was prepared by dissolving the EtBr powder (Amersco, 
Ohio, USA) in doubl.�" distilled water and stored in the dark at room temperature. 
2.1.7.4 Gel Loading Solution (6X) 
Loading dye was prepared by mixing 0.25% (w/v) bromophenol blue 
(Amersham, GE Healthcare, Buckinghamshire, England), 0.25% (w/v) xylene cyanol 
FF (ICN BioMwdicals Inc, Costa Mesa, CA, USA), and 40% glycerol (Amersham, GE 
Healthcare, Buckinghamshire, England) in autoclaved double distilled water. The stock 
was aliquoted and stored at -20°C while the working dye was kept at 4°C. 
2.1.7.5 GeneRulerTM loObp DNA Ladder and GeneRulerTM Ikb DNA Ladder 
Both ladders were purchased from Fermentas (Hanover, MD, USA). The 
ladders were prepared from diluting 1 part of DNA ladder with 1 part of 6X dye 
(supplied) and 4 parts of autoclaved double distilled water. The working ladders were 
stored at 4°C. 
2.1.7.6 Electrophoresis Apparatus 
Wide mini-sub cell GT systems were purchased from Bio-Rad Laboratories 
(Hercules, CA, USA). 
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2.1.8 Reagents for Zero-trans 3-OMG Influx in Erythrocytes 
2.1.8.1 3-O-Methyl-D-Gluco-Pyranose (3-OMG) 
3-OMG was purchased from Sigma (St. Louis, MO, USA). The powder was 
dissolved in IX PBS to a stock concentration of 10 mM and stored at 4°C until use. 
2.1.8.2 3-0-[methyl-^^C]-Methyl-D-GIucose (^^C-3-OMG) 
The stock solution (56.4 mCi/mmol) was purchased from PerkinElmer Life 
Science, Inc. (Boston, MA, USA) and stored at -20°C. 
2.1.8.3 Stop Solution 
The stop solution containing 100 [iM mercuric chloride and 50 |LIM phloretin in 
ice-cold IX PBS, was prepared immediately before used. 
2.1.8.4 Mercuric Chloride 
Mercuric chloride was purchased from Sigma (St. Louis, MO, USA). It was 
freshly prepared by dissolving 27.15 mg of mercuric chloride powder in 1 ml of IX 
PBS. 
2.1.8.5 Phloretin 
Phloretin was purchased from Sigma (St. Louis, MO, USA). It was freshly 
prepared by dissolving 13.75 mg of phloretin powder in 0.5 ml of 95% ethanol. 
2.1.8.6 Isopropyl Alcohol 
Isopropyl Alcohol was purchased from Sigma (St. Louis, MO, USA) and stored 
at room temperature. 
2.1.8.7 Solene-350 
Solene-350, which was used as tissue solubilizer, was purchased from Packard 
Bioscience (Meriden, CT, USA) and stored at room temperature. 
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2.1.8.8 Hydrogen Peroxide 30% (v/v) (H2O2) 
H2O2 was purchased from BDH Laboratory (Dorset England) and stored at 4°C. 
2.1.8.9 Liquid Scintillation Cocktail 
The OptiPhase HiSafe 2 scintillation fluid (PerkinElmer Life Science, Inc., 
Boston, MA, USA) was stored in the dark at room temperature. 
2.1.9 Reagents for Zero-trans 3-OMG Efflux from Erythrocytes 
2.1.9.1 Initiation Solution 
The initiation solution containing 1 mM mannitol (Sigma, St. Louis, MO, USA) 
in IX PBS was stored at 4°C. 
2.1.9.2 Stop Solution 
The stop solution containing 1 mM mannitol, 100 |LIM mercuric chloride and 100 
).iM phloretin in ice-cold IX PBS, was freshly prepared before used. 
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2.1.10 Reagents for Erythrocytes Membrane Extraction and Detection 
2.1.10.1 Lysis Buffer 
Lysis buffer containing 5 mM Na2HP04 and 0.1 mM PMSF (Amersham, GE 
Healthcare, Buckinghamshire, England) was dissolved in double distilled water. The 
pH value of the buffer was adjusted to 8.0 by 6 N HCl. 
2.1.10.2 Bovine Serum Albumin (BSA) 
BSA standard (Sigma, St. Louis, MO, USA) was prepared as 1 mg/ml stock in 
autoclaved double distilled water and aliquots of 300 )al were stored at -2()°C. 
2.1.10.3 Detergent Compatible (DC) Protein Assay Reagents 
DC protein assay reagents were purchased from Bio-Rad Laboratories (Hercules, 
CA, USA). It is a colorimetric assay for protein concentration following detergent 
solubilization. 
2.1.10.4 30% (w/v) Acrylamide/ Bis Solution, 37.5:1 
The ready-to-use 500 ml of acrylamide solution containing 30% (w/v) 
acrylamide (146.1 g) and N,N'-methylene-bis-acrylamide (3.9 g) and crosslinker ratio 
of 37.5:1 was purchased from Bio-Rad Laboratories (Hercules, CA, USA). It was light 
protected and stored at 4°C until use. 
2.1.10.5 Stacking Gel Buffer 
The buffer containing 0.5 M Tris-HCl buffer and 0.4% SDS, pH value of buffer 
was adjusted to 6.8 and kept at 4°C. 
2.1.10.6 Running Gel Buffer 
The buffer containing 1.5 M Tris-HCl buffer and 0.4% SDS, pH value of buffer 
was adjusted to 8.8 and kept at 4°C. 
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2.1.10.7 10% Ammonium Persulfate (APS) 
APS (10%, w,v) (Amersham, GE Healthcare, Buckinghamshire, England) was 
freshly prepared in double distilled water before use. 
2.1.10.8 N, N, N，，N'-Tetra-Methylethylenediamine (TEMED) 
TEMED purchased from Bio-Rad Laboratories (Hercules, CA, USA) was the 
last to add to initialize the polymerization of the SDS-polyacrylamide gel. It was stored 
at 4°C until use. 
2.1.10.9 SDS Gel Loading Buffer (4X) 
SDS gel loading buffer (4X) was prepared by mixing 0.8 ml of 0.05% (w/v) 
bromophenol blue, 1 ml of 0.5 M Tris-HCl at pH 6.8，1.6 ml of glycerol, 1.6 ml of 20% 
(w/v) SDS, 3.8 ml of double distilled water and 0.3 ml of 2-P-mercaptoethanol. The 
buffer was stored at 4°C until use. 
2.1.10.10 Prestained SDS-PAGE Broad Range Standard 
The prestained SDS-PAGE standard (broad range) was purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). It consisted of eight colored proteins including 
myosin (209,000 Da), p-galactosidase (124,000 Da), bovine serum albumin (80,000 Da), 
ovalbumin (49,100 Oa), carbonic anhydrase (34,800 Da), soybean trypsin inhibitor 
(28,900 Da), lysozyme (20,600 Da) and aprotinin (7,100 Da). The standard colored 
proteins prepared in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 7), 10 mM DTT, 2 
mM EDTA and 0.01% NaN^ were stored at -2()°C until use. 
2.1.10.11 Tris-Glycine-SDS Electrophoresis Buffer (lOX) 
The lOX electrode buffer containing 0.25 M Tris (Amersham, GE Healthcare, 
Buckinghamshire, England) at pH 8.3, 1.92 M glycine (Amersham, GE Healthcare, 
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Buckinghamshire, England) and 1% SDS in double distilled water was stored at room 
temperature. The IX working buffer was freshly diluted from lOX stock before use. 
2.1.10.12 Coomassie Blue Staining and Destaining Solution 
Staining Solution was prepared by dissolving 0.25 g of Coomassie R-250 from 
Bio-Rad Laboratories (Hercules, CA, USA) with 10 ml of acetic acid (Sigma, St. Louis, 
MO, USA), 50 ml of methanol (Sigma, St. Louis, MO, USA) and 50 ml of double 
distilled water. The mixture was stirred for 2 hours. For the destaining solution, it was 
prepared by mixing one volume of acetic acid, three volumes of methanol and ten 
volume of double distilled water. Both coomassie blue staining and destaining solution 
were stored at room temperature. 
2.1.10.13 Tris-Glycine Buffer (lOX) 
Tris-glycine buffer (lOX) containing 0.25 M Tris base and 1.9 M glycine in 
double distilled water was stored at room temperature. 
2.1.10.14 Tris-Glycine-Methanol Transfer Buffer (IX) 
The transfer buffer was prepared by mixing 100 ml of methanol with 100 ml of 
lOX concentrate of Tris-glycine buffer and 800 ml of double distilled water. The 
solution was freshly prepared before use. 
2.1.10.15 PolyScreen PVDF Hybridization Transfer Membrane 
The polyvinylidene difluoride (PVDF) membrane was purchased from 
PerkinElmer Life Science, Inc. (Boston, MA, USA) and kept at room temperature. 
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2.1.10.16 Tris-Buffered Saline (TBS) 
The lOX TBS concentrate was prepared by dissolving 0.2 M Tris base, 1.37 M 
NaCl，and 38 ml of 1 M HCl in 1 L of double distilled water and pH was adjusted to 7.6. 
The solution was stored at room temperature. 
2.1.10.17 TBS-Tween (TBS-T) 
TBS-T was prepared by adding 0.1% (v/v) Tween-20 in 100 ml of lOX TBS and 
900 ml of double distilled water. The solution was freshly prepared before use. 
2.1.10.18 Skimmed Milk Solution 5% (w/v) 
Skimmed milk powder (Carnation, Switzerland) was dissolved in TBS-T at a 
concentration of 5% (w/v). 
2.1.10.19 Goat Anti-GIutl Polyclonal Antibody (GIutlC-20) 
GlutlC-20 was raised against the C-terminus of Glutl was purchased from 
Santa Cruz Biotechnology (Santa Cruz, California, USA). It was supplied at a 
concentration of 200 ; ig/ml and stored at 4°C. 
2.1.10.20 Mouse Anti-Human Band 3 monoclonal Antibody 
This antibody was purchased from Sigma (St. Louis, MO, USA). It recognizes 
against the epitope located in cytoplasmic pole of Band 3 molecules and was stored at -
20�C. 
2.1.10.21 Rabbit Anti-Goat IgG 
Rabbit anti-goat IgG, peroxidase-linked species-specific whole antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA). It was 
supplied at a concentidtion of 0.4 mg/ml and stored at 4°C. 
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2.1.10.22 Goat Anti-Mouse IgG 
Goat anti-mouse IgG, peroxidase-linked species-specific whole antibody was 
purchased from Zymed Laboratory Inc., (San Francisco, CA, USA). It was supplied at 
a concentration of 0.4 mg/ml and stored at 4°C. 
2.1.10.23 ECIJM Western Blotting Detection Reagent 
The western blotting detection reagents (Amersham, GE Healthcare, 
Buckinghamshire, England) contain detection reagent 1 (250 ml) and detection reagent 
2 (250 ml) were light protected and stored at 4°C. 
2.1.10.24 X-Ray Film 
The X-ray film was purchased from Fuji Photo Products Co. Ltd. (Minato-Ku, 
Tokyo, Japan) and stored in the dark at room temperature. 
2.1.10.25 Electrophoresis Apparatus 
Mini-Protein 3 electrophoresis cell system was purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). 
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2.2 Methods 
2.2.1 GLUTl Gene Analysis 
2.2.1.1 cDNA Sequencing 
Two hundred microliters of blood sample was mixed with 800 |.il Trizol reagent 
(Invitrogen, Life Technologies, Carlsbad, California, USA) and incubated for 5 minutes 
at room temperature to allow complete dissociation of nucleoprotein complexes. Then 
the mixture was centrifuged at 17949 x g for 10 minutes at 4°C. The supernatant was 
transferred to a new 1.5 ml microcentrifuge tube and mixed with 300 \.i\ of chloroform 
(BDH Laboratory Dorset, England) followed by vigorous shaking for 15 seconds. The 
mixture was then inc(?bated for 2 minutes before subjecting to centrifugation at 17949 x 
g for 15 minutes at 4°C. Following centrifugation, the solution was separated into 2 
phases; the upper colorless aqueous phase was collected and transferred to another new 
1.5 ml microcentrifuge tube. It was then mixed with 750 of isopropyl alcohol to 
precipitate RNA. After standing for 30 minutes, the mixture was centrifuged at 15294 x 
g for 10 minutes at 4°C. The RNA pellet was washed with 1.5 ml of ice-cold 75% 
ethanol and followed by centrifugation at 6767 x g for 8 minutes at 4 � C . The ethanol 
was removed and the RNA pellet was air-dried for 20 minutes at room temperature. 
The RNA pellet was ihen redissolved in 30-50 |LI1 of DEPC-treated water and stored at -
80°C until use. The RNA concentration was quantified spectrophotometrically by 
BioPhotometer (Eppendorf, Hamburg, Germany) at 260 nm. The purity of RNA was 
estimated by the ratio of A260/A280 and was found to be greater than 1.7. The integrity 
of the extracted total RNA was checked by gel electrophoresis on 1% agarose gel and 
two predominant bands of 18S and 28S ribosomal RNA were visualized in the ratio 1:2. 
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2.2.1.2 Reverse Transcription (RT) 
Total RNA extract was used as template for generating cDNA using M-MLV 
reverse transcriptase. RT reaction was performed using 5 fig of total cellular RNA for a 
20 jil-reaction mixture following the manufacturer's protocol. Briefly, template RNA 
was first mixed with 1 i^l of lOOmM (0.5 |ug) oligo(dT)i5 and incubated at 7 0 � C for 5 
minutes to denature the RNA. Then, 4 of 5X reaction buffer, 1 fil of 40 mM dNTP, 
0.5 |Lil ( � 1 5 U) of RNAguardTM ribonuclease inhibitor and 3.3 of DEPC-treated 
water were added to the mixture. After a further incubation at 37°C for 5 minutes, 0.2 
111 of M-MLV reverse transcriptase (200 U/ |al) was added. The 20 i^l of reaction 
mixture was incubated at 3 7 � C for 90 minutes followed by 70°C for 10 minutes to 
inactivate the reverse transcriptase and then cooled to 4 � C . The resulting cDNA sample 
was stored at -20°C until use. 
2.2.1.3 PCR 
PCR was performed in a 50 \x\ of reaction mixture containing 1 of cDNA, 5 
|Lil of lOX reaction buffer, 0.4 of 40 mM dNTP mix, 1 unit of Pfii DNA polymerase, 
1 of 10 (iM of both forward and reverse primers by the Mastercycler gradient 
(Eppendorf, Hamburg, Germany). 
Forward Primer: 
5' -ATG GAG CCC AGC AGC AAG AAG CTG ACG GGT CGC-3’ 
Reverse Primer: 
5' —TCA CAC TTG GGA ATC AGC CCC CAG GGG ATG GAA-3’ 
The amplification temperatures were 95°C for 5 minutes, 95�C for 30 seconds, 
55°C for 30 seconds, and 72°C for 90 seconds. After 39 cycles, a final extension was 
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done at 72°C for 10 minutes. The amplification products were visualized by EtBr 
staining 1% agarose gels. 
2.2.1.4 Gel Purification 
The band with appropriate size was excised from a 1% agarose gel followed by 
gel purification using GeI-M�M Extraction System (Viogene, Oberhausbergen, 
France). Five hundred milliliters of GEX buffer were added to dissolve the gel and 
incubated at 60°C for 5 minutes with occasional shaking. After the agarose gel was 
completely dissolved, the mixture was allowed to cool down to room temperature 
before transferring th：". mixture solution to the Gel-M"^ column. The column was spun 
at 16000 X g for 1 minute and the flow-through was discarded. In order to wash the 
DNA bound on the column, 700 of WF buffer was added and centrifuged at 16000 x 
g for 1 minute and this step was repeated once with 500 i^l of WS buffer. Any residual 
washing solution was thoroughly removed by spinning at 16000 x g for additional 3 
minutes. The column was then placed in a new 1.5 ml microcentrifuge tube and 40 
of autoclaved double distilled water was added to elute the bound DNA. After standing 
for 1 minute at room temperature the column was spun at 16000 x g for 1 minute. DNA 
concentration was quantified spectrophotometrically by Biophotometer (Eppendorf, 
Hamburg, Germany) and stored at -20°C. The PGR products were subjected to 
sequencing analysis by Macrogen Inc. (Seoul, Korea) to identify mutation. 
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2.2.1.5 TA Cloning of GLUTl Gene 
GLUTl gene was amplified following the PCR protocol stated in Section 2.2.1.3， 
except Taq polymerase was used instead. The PCR products were then resolved by 1% 
agarose gel electrophoresis and recovered using the Gel-M™ Gel Extraction System 
(Viogene, Oberhausbergen, France). Then 4 \x\ of PCR product was mixed with 1 of 
salt solution and 1 of TOPO vector provided in the TOPO TA Cloning® kit. The 
reaction mixture was mixed gently and incubated for 5 minutes at room temperature. 
Meanwhile, chemically competent E. coli provided in the kit was thawed on ice. After 
ligation, 2 of the cloning reaction was added into the vial of competent cells and 
mixed gently. The reaction mixture was then incubated on ice for 15 minutes. The cells 
were heat-shocked for 30 seconds at 42 °C without shaking and then transferred back to 
ice immediately. Then 250 of room temperature SOC medium provided in the kit 
was added and the reaction mixture was subsequently incubated at 37 °C for 1 hour 
with shaking for recovery. Afterwards, 100 |il from the transformation mixture was 
spread over a pre-warmed LB agar plate supplemented with ampicillin (50 ^ig/ml) and 
incubated at 37 °C overnight. Twenty colonies were picked and checked by PCR 
amplification. Positive clones were allowed for overnight culture in LB broth containing 
50 |Lig/mI amplicillin at 37 °C. The plasmid DNA was then harvested by minipreps kit 
and subjected to sequencing analysis by Macrogen Inc. (Seoul, Korea). 
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2.2.1.6 Genomic DNA Extraction 
Genomic DNA was extracted from white blood cells by QIAamp DNA Blood 
Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Briefly, 
2 ml of whole blood was first mixed with 200 \il of QIAGEN protease in a 15 ml 
centrifuge tube. After mixing thoroughly, 2.4 ml of Buffer AL was added and mixed by 
vortexing. Then the mixture was incubated at 70°C for 10 minutes to lyse the blood 
cells. After the incubation, 2 ml of absolute ethanol was added to the mixture, which 
was then transferred to a QIAamp Midi column placed in a 15 ml centrifuge tube. The 
tube was centrifuged at 1811 x g for 3 minutes and the filtrate was discarded. Without 
moistening the rim, 2 ml of Buffer AWl was added to the QIAamp Midi column and 
was centrifuged at 3220 x g for 4 minutes. Then, 2 ml of Buffer AW2 was added to the 
QIAamp Midi column and centrifuged at 3220 x g for 30 minutes. In order to remove 
any residual ethanol, the column was incubated at 70°C for 10 minutes before the 
recovery step. Thre-j hundred microliters of autoclaved double distilled water was 
added to the column and incubated at room temperature for 5 minutes before subjecting 
to centrifugation at 3220 x g for 10 minutes. Another 300 i^l of autoclaved double 
distilled water was added to the column to maximize the DNA yield by centrifuging at 
3220 X g for 10 minutes. The DNA concentration was quantified 
spectrophotometrically by BioPhotometer at 280 nm. The extracted genomic DNA was 
stored at 4°C for routine use or at -20°C for long-term storage. 
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2.2.1.7 Amplification of the 10 Exons of GLUTl Gene 
Genomic DNA was used as template for PGR with primers specific to each of 
the exon-intron boundaries of the human GLUTl gene as shown in Table 2.2.1 (Tao et 
al., 1995). PCR was performed in a 50 \i\ of reaction using 0.2 \JLg of genomic DNA as 
template as described in Section 2.2.1.3. The amplification temperatures were 95°C for 
5 minutes, 95°C for 30 seconds, corresponding annealing temperature for 30 seconds, 
and 11�C for 30-50 seconds depending on the product size. After 39 cycles, a final 
extension was done at 72°C for 10 minutes. The amplification products were visualized 
by EtBr staining 1% agarose gels. For the amplification condition of Exon 1, 6% 
DMSO was added to resolve the high GC content of this fragment. 
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Table 2.2.1 Primer pairs used in GLUTl gene analysis (Tao et al” 1995) 
Annealing 
Exon Primer set temperature Size 
CO (bp) 
Forward: 
1 5'-AAC AGC GAG CGT GCC GGT CGC TAG A-3' 59.0 280 
Reverse: 
5,-TAA GGC GGG CAG GAG TCT GCG CCT T-3, 
Forward: 
2 5'-CTC CCA GAC ACG CCT ATA ACA GT-3' 65.0 173 
Reverse: 
5,-GGC TGG TGT CCA TAA GCC AAC G-3, 
Forward: 
3 5'-GCT TGC TCA CCC AGG CTG CAT-3' 68.0 227 
Reverse: 
5’-TCC AAG GGC AGT GCC AGG AC-3, 
Forward: 
4 5'-ACC AAT GTG GGC ACT GGC CT-3' 65.0 314 
Reverse: 
5,-GTG CCA GGC AGG TAG ATC CT-3’ 
Forward: 
5 5'-AAA GGG GGT CAG GGC AGA GGC GCT CA-3' 72.6 313 
Reverse: 
5’-GTG GGA AGA AGG CCA GGG CTC AGG GA-3, 
Forward: 
6 5'-ACT CTG AGC CAC CCT CAC CTT CCC T-3' 68.0 281 
Reverse: 
5’-ACA CTT GAC CAG AGG GCT TGG CTG G-3, 
Forward: 
7 5'-CAG GTA GGC CCC AAC AGT TTC TC-3' 61.3 170 
Reverse: 
5，-TGG CTG GGG GGG CCA GTA AGC-3’ 
Forward: 
8 5'-AGG GGT GGC ACT GAC ATG TCT CT-3' 61.3 166 
Reverse: 
5,-GCA T C C C r C ACT CTC CAG AAC CT-3, 
Forward: 
9 5'-AAC TTT TCC CCC TCT CCG TCA TC-3' 65.0 270 
Reverse: 
5’-GTG CGG GTG AGT ATA GAG ACA GT-3, 
Forward: 
10 5'-ATG ACT CCA ACC AAG TGT GTC-3' 65.0 297 
Reverse: 
5,-TGT GCT CCT GAG AGA TCC TTA-3’ 
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2.2.1.8 Gel Purification 
The band with correct size was excised from a 1% agarose gel followed by gel 
purification step as described in Section 2.2.1.4. DNA concentration was measured and 
stored at -20�C. The PCR products were subjected to sequencing analysis by Macrogen 
Ltd. to identify mutal: Dn. 
2.2.2 Zero-trans 3-OMG Influx into Erythrocytes 
2.2.2.1 Preparation of Erythrocytes 
Blood samples (1-2 ml) were washed twice with ice-cold IX PBS and 
centrifuged at 805 x g for 4 minutes at 4°C. The supernatant was discarded, and 
erythrocytes were then incubated with IX PBS on wet ice for 15 minutes to establish 
zero-trans i.e. no intracellular glucose, condition. After incubation blood sample was 
centrifuged again at 805 x g for 4 minutes at 4°C, and supernatant was removed. Then 
erythrocytes were re-suspended in IX PBS to the original blood sample volume. 
Subsequently, 50 |al of erythrocytes were aliquoted in 1.5 ml microcentrifuge tubes for 
assay, and 10 were used for cell counting using Bright-Lin hemacytometer (Sigma, 
St. Louis, MO, USA). 
2.2.2.2 Zero-trans 3-OMG Influx into Erythrocytes 
The Lowe and Walmsley techniques were modified as previously described 
(Lowe and Walmsley, 1986; Klepper et al, 1999b). Briefly, the 50 \i\ aliquot of 
erythrocytes was incubated with 100 hot and cold (H/C) mixture in IX PBS 
containing 1 |aCi/ml of '^C-labeled 3-OMG and 0.6 mM of cold 3-OMG. Time course 
zero-trans influx of ^"^C-labeled 3-OMG was conducted over a period of 30 seconds at 
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5-second intervals. Equilibrium uptake of ^"^C-labeled 3-OMG was measured after 25 
minutes incubation. All above steps were performed at 4°C. 3-OMG influx was 
terminated by rapid addition of 1 ml of ice-cold stop solution and erythrocytes were 
spun down (low speed for 20 seconds) followed by washing steps performed at room 
temperature. The erythrocytes pellet was washed twice using 1 ml of ice-cold stop 
solution. The pellet in each tube was then lysed with 250 f.il of solubilizing agent 
containing Soluene-350 and isopropyl alcohol (in the ratio: 2:1 v/v). Afterwards, the 
sample was transferred to scintillation vial and bleached with 250 |LI1 of 30% H2O2. The 
mixture was swirled until all foaming subsided. OptiPhase HiSafe 2 scintillation fluid 
(4 ml/sample) was added, and cell-associated radioactivity in aliquots was 
determined by a Beckman LS 6500 multi-purpose scintillation counter (Beckman 
Coulter, Inc., Fullerton, California, USA). 
2.2.3 Zero-trans 3-OMG Efflux from Erythrocytes 
2.2.3.1 Preparation of Erythrocytes 
Blood sample (1 ml) was washed three times with ice-cold IX PBS in a 15 ml 
centrifuge tube and centrifuged at 805 x g for 4 minutes at 4 � C . The packed 
erythrocytes were re-suspended in ice-cold IX PBS at 50% hematocrit (2 ml). 
2.2.3.2 Zero-trans 3-OMG Efflux from Erythrocytes 
Sugar efflux under zero-trans condition was assayed essentially as described 
previously (el-Barbary et al., 1996). Briefly, the aliquot of packed erythrocytes was 
incubated at 3 7 � C fo: an hour at 5% hematocrit in IX PBS containing 1 mM 3-OMG. 
The 3-OMG loaded cells were centrifuged at 1000 x g for 10 minutes at 4°C. The 
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supernatant was discarded until < 1.5 ml left and the loaded cells were transferred to a 
1.5 microcentrifuge tube. After centrifuging briefly, the supernatant was further 
removed to 50% hematocrit. A hundred microliters of erythrocytes were used for cell 
counting using Bright-Lin hemacytometer and 500 of loaded cells were transferred to 
a new 1.5 microcentrifuge tube for further treatment. The aliquot of 3-OMG loaded 
cells were then loaded with 56 jaCi '"^C-labeled 3-OMG/ 100 i^l of erythrocytes at 37°C 
for 30 minutes. After the incubation, 10 \i\ of aliquots were taken for assay. Efflux was 
started by the rapid addition of 200 |LI1 of ice-cold initiation solution. A time-course 
zero-trans efflux of i t- labeled 3-OMG was conducted over a period of 120 seconds. 
Equilibrium efflux of ^"^C-labeled 3-OMG was measured after incubating for 10 minutes. 
3-OMG efflux was terminated by rapid addition of 1 ml of ice-cold stop solution and 
erythrocytes were spun down (low speed for 20 seconds) followed by washing steps 
performed at room temperature. The erythrocytes pellet was washed twice using 1 ml 
of ice-cold stop solution. The pellet in each tube was then lysed with 250 \i\ of 1% 
SDS. Afterwards, the sample was transferred to scintillation vial and bleached with 250 
|il of 30% H2O2. The mixture was swirled until all foaming subsided. OptiPhase 
HiSafe 2 scintillation fluid (4 ml/sample) was added, and cell-associated 
radioactivity in aliquot was determined by a Beckman LS 6500 multi-purpose 
scintillation counter. 
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2.2.4 Glutl Protein Expression 
2.2.4.1 Preparation of Erythrocyte Membrane Proteins 
Erythrocyte membrane proteins are isolated by the simple hypotonic osmotic 
lysis method (Baldwin et al., 1982). Blood sample (3 ml) was washed three times with 
50 ml of ice-cold IX PBS and centrifuged at 1000 x g for 4 minutes at 4°C. The 
supernatant was discarded leaving the erythrocyte pellet. After that, 50 ml of ice-cold 
lysis buffer was added and centrifuged at 10000 x g for 15 minutes at 4°C. The 
supernatant was then discarded. Then 50 ml of lysis buffer was added to the tube and 
centrifuged again. These steps were repeated until the fluffy pellet (membrane fraction) 
was clear. 
2.2.4.2 Quantificatif n of Proteins 
Protein concentration was estimated by the detergent-compatible protein assay 
system from Bio-Rad Laboratories (Hercules, CA, USA) with BSA as standard. BSA 
solutions at 0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml, 0.8 mg/ml and 1.0 mg/ml were prepared 
with lysis buffer in duplicate from 1 mg/ml BSA stock solution by serial dilution. 
Diluted BSA standards or protein samples (12.5 |_d) were mixed with 62.5 i^l of reagent 
A，(20 |il of reagent S per 1 ml of reagent A), followed by addition of 500 i^l reagent B 
in a 1 ml plastic cuvette. The reaction mixture was allowed to stand for 15 minutes in 
dark at room temperaiure. Absorbance of both standards and samples were measured in 
duplicate, at 750 nm was recorded using the dye as a blank. The concentrations of 
proteins samples were determined spectrophotometrically by BioPhotometer 
(Eppendorf, Hamburg, Germany). 
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2.2.4.3 Western Blot Analysis 
SDS-PAGE was performed to compare the Glutl expression level between 
GlutlDS patient and normal subjects. Table 2.2.2 shows the composition of the 
chemical reagents needed for casting a 10% SDS-polyacrylamide gel. Twenty 
micrograms of protein samples were mixed with 4X SDS gel loading buffer before 
loading to the 10% SOS-polyacrylamide mini-gel. Five microliters of prestained SDS-
PAGE broad range standards were loaded as molecular weight marker and the gel was 
run under constant voltage of 100 volts for 2 hours. 
Table 2.2.2 Composition of 10% SDS-polyacrylamide gel 
Reagent 5% Stacking Gel 10% Running Gel 
30% Acrylamide Stock 0.825 ml 1.666 ml 
Stacking Gel Buffer 1.25 ml -
Running Gel Buffer - 1.25 ml 
Distilled Water 2.875 ml 2.034 ml 
10% APS 50 |Li l 50 III 
TEMED 3.3 |li1 3.3 i^l 
After electrophoresis, the stacking gel was removed. The gel was then rinsed 
briefly with distilled water to remove any residual SDS that could hinder protein 
transfer. A piece of PVDF membrane was first soaked in methanol, then together with 
two pieces of Whatmann 3 MM chromatography papers and two pieces of spongy were 
pre-wetted with transfer buffer. They were assembled in the wet blotting apparatus 
from Bio-Rad Laboratories (Hercules, CA, USA). Air bubbles were eliminated by 
rolling a plastic tube on the membrane to avoid uneven transfer. The proteins on the gel 
were then electroblot ed onto the PVDF membrane at 100 volts for 2 hours. The whole 
apparatus was placed in an ice bath to facilitate heat dissipation. After the transfer, the 
membrane with transferred proteins was rinsed with TBS-T. The membrane was then 
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blocked with TBS-T containing 5% skimmed milk for 1 hour at room temperature. The 
Glutl protein was then identified using a GlutlC-20 antibody at 1:5000 dilutions in 5% 
skimmed milk at 4°C overnight. After blotting with GlutlC-20, the membrane was 
washed 3 times with TBS-T for 5 minutes. After washing, the membrane was incubated 
with horseradish peroxidase-linked secondary antibody at 1:10000 dilutions in 5% 
skimmed milk for 1 hour at room temperature. Then the membrane was washed with 
TBS-T for 5 minutes 3 times. After washing, the membrane was subjected to ECL 
assay to detect the expression level. In addition, the membrane was probed with anti-
human band 3 antibody which served as a control protein. After blocking with 5% 
skimmed milk for 1 hour，the membrane was blotted with anti-human band 3 antibody 
at 1:10000 dilutions in 5% skimmed milk at room temperature. After 1 hour of 
incubation, the membrane was then washed and probed with secondary antibody 
identically to that of GlutlC-20, followed by ECL assay detection. 
2.2.4.4 Enhanced Chemiluminescent (ECIJM) Assay 
Equal volumes of ECI /M detection reagent 1 was freshly mixed with detection 
reagent 2 and pipet/ed onto the membrane. For each cm^ of membrane, 10 of 
detection reagent was required. The membrane was wrapped with cling wrap so that 
the surface of the membrane was covered with the detection reagent evenly and was 
allowed to react for 1 minute. The membrane covered with cling wrap, was placed with 
the protein side facing the x-ray film inside the film cassette. The film was allowed to 
expose in the dark for 30 seconds before development. 
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2.2.5 Statistics 
All experiments were repeated at least twice with similar results obtained. 
Results shown are from a single experiment representative of similar experiments. 
Each data point is expressed as mean 士 S.D. (standard deviation) unless otherwise 




2.3.1 Molecular Analysis of the GLUTl Gene of a Suspected GlutlDS Patient 
The patient in the present study shows clinical features of GlutlDS, such as the 
infantile-onset seizure, low CSF/ blood glucose level and low absolute CSF glucose 
level. De Vivo and his collaborators found that the CSF glucose values of GlutlDS 
patients seldom exceed 40 mg/dL (De Vivo et al., 2002b). In this patient, the absolute 
CSF glucose value is 38 mg/dL. These clinical signatures persuade us to believe that 
the patient is suffering from GlutlDS, therefore, DNA sequencing analysis and several 
functional assays were performed to confirm the condition. 
In order to identify a mutation that might be present in the GLUTl gene of the 
patient, the entire GLUTl gene was amplified from the cDNA obtained by RT-PCR and 
the 10 exons of GLUTl gene were amplified separately from genomic DNAs of both 
the patient and the parents. Amplicons were subjected to automated sequencing 
analysis and the sequencing result of the entire GLUTl gene amplified from the 
patient's cDNA showed a heterozygous result, which was caused by a novel insertion 
mutation (Fig. 2.3.1 A). 
A) 
170 180 190 200 
C GAG CAGC TG TC TG GCC TCC TG TC TGGCATC TAG TA T _ u Al . dL k 
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B) 
170 180 190 200 
：CCA G CAG C TG TC TGGCATCAAC GCTGTG AG TGCCCC C 
mkikmik 
Figure 2.3.1 Automated DNA sequencing identified a novel heterozygous insertion 
mutation in patient GLUTl gene. DNA sequencing results using cDNA template 
amplified from RNA extracted from blood sample. DNA sequence of A) the patient 
cDNA showing a heterozygous mutation, B) maternal control showing the normal 
GLUTl cDNA sequence. 
This mutation was then confirmed by the sequencing analysis of the patient's 
genomic DNA. A heterozygous sequencing result is located in exon 6 that starts at the 
nucleotide position 1022 (numbering according to the GenBank NM_006516) and at the 
end of exon 6，12 extra base pairs were found (Fig. 2.3.2). 
70 180 190 200 iCCAGCAGCTGTCTGGCCTCCTGTCTG GGATTGACCCT 
J I MMfLkMlMiM/i 
Figure 2.3.2 Automated DNA sequencing showing the novel heterozygous insertion 
mutation in patient GLUTl exon 6. DNA sequence results using genomic DNA 
extracted from blood samples. DNA sequence of the patient GLUTl exon 6 showing a 
heterozygous mutation. 
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The heterozygousity of this mutation was further resolved by the sequencing 
analysis of TA cloning. From the sequencing result (Fig. 2.3.3), 3 populations of clones 
were isolated and one of them revealed a 12 extra base pairs (CAG CAG CTG TCT) 
insertion in exon 6，however, these inserted sequences are the tandem duplication of 
nucleotide 1023 to 1034，so it is impossible to find out whether this mutation is inserted 
after 1022 or 1034. This novel insertion mutation was termed 1034-1035Insl2. This 
mutation was only found in the patient but not in the parents (Fig. 2.3.1 B)，which 
implied it is a sporadic heterozygous insertion mutation. 
A) 
280 290 300 310 
CCAGCAGCTGTCTCAGCAGCTGTCTG GCAT CAACG C TG 
ftikJikMiyyUi 
B) 
280 290 300 310 
CCAGCAGCTGTCTGGCATCAACG C TGTG AGTGCCCC CAC 
i 
l A 』 _ k i i l f c 
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C) 
280 290 300 310 
:CAGCAGCTGTCTGGCCTCCTGTCTGGGATCGCCCCTG ‘ 
ill ^ y 
編棚 kMMkMAk 
Figure 2.3.3 Automated DNA sequencing showing the heterozygousity of 1034-
1035Insl2 mutation by TA cloning. DNA sequencing of fragment generated by TA 
cloning showing A) the homozygous 12 nucleotide insertion mutation, B) normal 
GLUTl sequence between nucleotide 1034-1035 and C) heterozygous insertion 
mutation. 
2.3.2 Functional Analysis of the GlutlDS Patient's Glutl protein 
As the patient is suffering from low glucose level in CSF，it is suspected that the 
Glutl protein might possess a ftinctional defect. To evaluate the function of the Glutl 
protein of the patient, several functional assays were performed. The glucose uptake 
activity of Glutl protein was studied by the zero-trans 3-OMG entry into the 
erythrocytes, and the results between the patient and the parental controls show no 
difference (Fig. 2.3.4 A and B), which suggests that the patient's Glutl protein 
transports glucose as efficiently as the parental controls'. The glucose transport kinetics 
of Glutl protein was evaluated by zero-trans 3-OMG influx, which was determined as a 
function of substrate concentration in erythrocytes (Fig. 2.3.4 C). The half saturation 
constant and Vmax of patient and parental controls were shown in Table 2.3.1，the kinetic 
parameters of the 3 subjects have no significant difference. The mutation does not alter 
the capacity and substrate affinity of Glutl protein. However, in repeated zero-trans 3-
OMG influx assay, an unexpectedly high cell-associated radioactivity counts was 61 
observed at the equilibrium state, i.e. t = 25 min (Fig. 2.3.4 A inset). This unanticipated 
result suggested that the patient might possess a defect in the efflux of glucose instead 
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Figure 2.3.4 Normal zero-trans 3-OMG transport into patient and parental 
erythrocytes. A) Zero-trans influx of 3-OMG into erythrocytes over 30 seconds in 
patient and his parents (two determinations/data point). Results were expressed as 
uptake pmol 10 RBC'^ versus time in seconds. Insert: 3-OMG uptake at equilibrium 
state. * Significant different between patient and parental controls. B) Kinetic analysis 
of 3-OMG uptake by erythrocytes in patient and his parents (four determinations/data 
point). Uptake was measured over 15 sec in the presence of concentrations of 3-OMG 
ranging from 0.6-10 mmol/1. C) Km and Vmax values were determined by a double-
reciprocal plot of 3-OMG transport velocity (v) in fmol s'^  10^ RBC'^ vs. substrate 
concentration [3-OMG] in mmol/1 and the kinetic values were indicated in Table 2.3.1. 
Table 2.3.1. Kinetic Parameters of Glutl protein of patient and parental controls 
S a m p l e s V 薩(fmol/sec/lO' RBC) K^ (mmol/1) 
Mother 1976士536 2.07士 0.12 
Patient 2500士833 3.03士 0.21 
Father 2611 士674 2.57 士 0.40 
Since Glutl is responsible for the bidirectional glucose transport, the high 
radioactivity counts at equilibrium state may imply a defect in its glucose efflux ability 
instead of the influx. The zero-trans 3-OMG efflux from erythrocytes showed a 
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significantly higher cell-associated '"^ C- radioactivity counts in the patient, as 
anticipated. A high cell-associated radioactivity counts in the patient indicated that 
less i4c-labeled 3-OMG was transported out. In other words, the glucose efflux activity 
of the patient Glutl protein was lower than those of the parental controls. The reduction 
is about 40% compared to control (Fig. 2.3.5). Cytochalasin B, a Glutl inhibitor served 
as a control to inhibit glucose efflux. 
1401 O mother 
T • patient 
120 - T • father 
- - “ T “ “ • cytochalasin B 
I i 
震 4 � . 
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Figure 2.3.5 Reduced zero-trans 3-OMG efflux from patient erythrocytes. Isolated 
erythrocytes were loaded with 1 mM '"^C-labeled 3-OMG. Time course assay of zero-
trans efflux of 3-OMG from erythrocytes over a period of 120 seconds in patient and his 
parents (two determinations/data point). Results were expressed as percentage of efflux 
at t = 0. * Significant different between patient and parental controls. 
2.3.3 Glutl Protein Expression in the GlutlDS Patient 
According to the results of the functional assays, the 1034-1035Insl2 mutation 
reduced the glucose efflux activity of patient's Glutl protein. This mutation was 
speculated to produce a defective Glutl protein in the patient, which is unable to 
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transport glucose out of the erythrocytes properly. Following the functional assays, the 
expression of Glutl protein was also examined. Fig. 2.3.6 showed the expression of the 
Glutl protein extracted from the erythrocytes of the patient and the parental controls. A 
broad band of Glutl with a molecular mass of 45-60 kDa was observed in all of the 3 
subjects. However there was an unexpected prominent lower molecular weight band 
(-37 kDa) present only in the patient's protein sample. Protein degradation or 
deglycosylation of protein may account for this unexpected band. Band 3 (96 kDa) was 
a membrane protein that served as the loading control in the experiment. 
Mother Father Patient 
似 k D a — ^ ^ ^ ^ ^ ^ L G l u t l 
= 誦 
N ^ H B M H Band 3 
Figure 2.3.6 An extra low molecular band identified in western blot analysis of 
erythrocyte membrane Glutl of patient. Twenty micrograms of erythrocyte 
membrane proteins were subjected to SDS-polyacrylamide gel electrophoresis and 
probed with antibodies specific for Glutl or Band 3. 
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2.4 Discussion 
This novel 1034-1035Insl2 mutation is a duplication of its adjacent 12-
nucleotide sequence,. The mutation is predicted to encode for 4 extra amino acid 
residues, Q^^^QLS, at transmembrane segment 7 of the Glutl protein. This QQLS motif 
is conserved among the members of the class I Glut family including Glutl, 3-5，7，8 
and HMIT (Joost and Thorens, 2001b). 
A) B) 
^ f j ^ K 产 OWTl YRQPILIAW LQLS QQLSbl NAVFYY3TSI GIOT2 YRQPILVAJUH LHV； QQTS U NOirmfSTSI 
MJ? g f l i OLt7T3 TRQPIIISIV hQU QQLS H MI^ VPYYSTGI 
G^tJTi HRQPLIIAW LQh^QQLSn NAVFYYSTSI 疆 ^p： GLUTS LRWQLLSIIV LKQC QQLS 3V NAIYYVADQI 
- f ® ^ ^ GLUT? LRWQLLSIIV LMAC QQLS 31 HAIMYYADTI 
~ L A ) 恥 则 VRWOWTVIV TMAC YQLC 3L NAIWFYTNSI 
^ ^ f f ^ T ^ ^ ^ Y , ' � ^ ^ CJLOTll U^QVTSLW LGSJ MELC m DSVYAYASSV 
L _ _ / \ [D/ERAGRR] GLDT6 VCRPITVM-L HKLI QQhl 31 TFILVYLOSX 
.4 乂 GLDT8 lYKPFIIOVS LMAI QQLS 3V NAVKFYAETI 
^ S . GLUTL0 MRORTTVGLG LVU QQLI 3Q PNVLCYASTI 
( J <5LUT12 MRTRIKIGLT LVPI VQIT PMTLPYASTV V ) HHIT TRRALIVOCO LQX! QQLS 91 NTIKYYSATI 
V y ^ 涯 
Figure 2.4.1 A) Schematic model of Glutl protein (partial). The QQLS motif is 
characteristic of class I Glut members. B) The sequence alignment among different 
members of the Glut family. The QQLS motif is conserved in Glut 1，3-5, 7, 8 and 
HMIT (Adapted from Joost and Thorens, 2001b). 
This mutation is located at the transmembrane segment 7 of the Glutl protein 
and it has been proposed that this segment takes part in the glucose permeation pathway 
(Hruz and Mueckler, 1999). Transmembrane segment 1 (Heinze et al., 2004), 2 
(Olsowski et al., 2000), 5 (Mueckler and Makepeace, 1999)，7 (Hruz and Mueckler, 
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1999), 8 (Mueckler and Makepeace, 2004), 10 (Mueckler and Makepeace, 2002) and 11 
(Hruz and Mueckler, 2000) of Glutl protein model have been proposed to form an 
helical bundle that comprises a water-accessible cavity within the cell membrane that 
allow glucose molecule to transverse through (Mueckler and Makepeace, 2005). It has 
been reported that by using the Xenopus laevis expression system, Q282C and Q283C 
mutations resulted in a significantly decrease in 2-deoxyglucose (2-DOG) uptake 
activity (Hruz and Mueckler, 1999). The sequence Q^^^QLSGINAVFYY^^^ in TMD 7 
of Glutl is suggested to have a role in both hydrogen bonding to D-glucose and closing 
the exofacial site during the transport catalysis process (Mori et al., 1994). It is also 
identified that this region Q^^^QXSGXNXXFYY^^^ is highly conserved in all members 
of the wider glucose transporter superfamily (Mori et al., 1994)，and plays an important 
role in binding exofacial ligands. It is especially true in the case of which is 
proposed to be responsible for exofacial glucose binding by contributing some of the 
hydrogen bonding groups to CI, C3 and ring-oxygen of glucose (Mori et al, 1994). All 
the previous studies were focusing on single point mutation in the QQLS motif and the 
importance of individual residues was elucidated, however this patient is suffering from 
an insertion mutation. This mutation resulted differently from those point mutations 
reported. Based on the results of functional assays, the glucose uptake activity of the 
patient's erythrocytes showed no significant reduction. Instead, the 3-OMG efflux 
activity of patient was significantly lower than the parental controls. This may provide 
another angle in studying the transport mechanism of the Glutl protein apart from 
studying the residue individually, a whole motif could also be considered. 
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This insertion mutation may affect the cooperation among the Glutl protein 
complex since Glutl functions as a monomer/tetramers. In a proposed model of the 
mechanism of glucose transport in Glutl protein it is suggested that the Glutl protein 
would shift from an outward facing to an inward facing conformation when transporting 
glucose molecules (Bamett et al., 1973). Upon the conformational alternation glucose 
molecules are then transported in and out of cells (Fig. 2.4.2). The mutation found 
might affect the structure of Glutl, hence, affecting the conformational flexibility of the 
Glutl complex. Therefore, the conformational alternation of the protein might be 
disturbed. This may result in a lower recovery rate from inward facing to outward 
facing conformation, leading to a reduced glucose efflux activity. The defective efflux 
activity of Glutl protein will affect the glucose export from the RBC to the brain 
endothelial. In addition, the export of glucose from the brain endothelial cells into the 
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Figure 2.4.2 Model for glucose transport by Glutl protein. Transporter exists in 2 
conformations. In Ti the glucose-binding site is exposed to the extracellular 
environment, and in T2 the binding site is exposed to the cytosol. Upon the binding of 
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glucose, a conformational change from T] to T2 occurs (Adapted from Nelson and Cox, 
2000). 
Furthermore, the result of erythrocytes zero-trans 3-OMG influx assay may not 
be conclusive to our knowledge there is a mutation that was reported to be "normal" in 
the assay but was later found to be pathogenic in the Xenopus oocyte study (Wang et al, 
2005). The blood assays were performed at 4°C，because the activity of Glutl in 
erythrocytes was so high that the uptake of glucose attains equilibrium in just a few 
seconds at the physiological body temperature, 37°C. However, the low temperature 
will affect the fluidity of the plasma membrane and subsequently affect the function of 
integral membrane pi Jteins like Glutl, i.e. the activity of Glutl protein is temperature-
dependent. Hence, the possibility that this mutation may also affect the glucose uptake 
activity cannot be eliminated at this point. 
Apart from the functional deficiency resulted from the mutation; the Glutl 
protein expression was also affected. In other reported mutations, Glutl 
immunoreactivity was either reduced (Seidner et al., 1998) or normal (Klepper et aL, 
2001a). Based on the result of the western blot, the insertion mutation is likely 
responsible for the lower molecular band which was prominent in the patient sample 
when compared to the parental controls (Fig. 2.3.6). Interestingly, the molecular size of 
this lower band (37 kDa) is similar to the size of the Glutl protein that lacks the N-
glycosylation (38 kDa- 39 kDa) (Asano et al., 1991; Asano et al. 1993). This mutation 
may enhance the susceptibility of the Glutl protein to deglycosylation and result in the 
prominent lower band observed in the patient's sample. Moreover, it is reported that 
69 
the lack of N-glycosylation would shorten the half-life of the Glutl protein (Asano et al. 
1993). Therefore, the smear (-29 kDa) found in the patient sample maybe the 
degradation products of the prominent lower band that was speculated to be the 
unglycosylated form of Glutl. 
Upon receiving the blood samples from our collaborator, experiments were 
performed as soon as possible. However, there was still a 24-hour time lag between the 
sample collection and sample processing, since these samples were originated from 
Japan. From our experience, the blood samples usually remained in good condition. 
Yet, hemolysis was observed occasionally. In the case discussed in this chapter, the 
first batch of blood samples showed mild hemolysis, and functional assays were still 
performed. Another batch of samples was sent to us later for further experiments. The 
condition of the latter batch of blood samples was better and no hemolysis was observed. 
No Significant difference was seen comparing the results obtained from the two batches 
of blood samples. However, the effects of shipping delay on the degradation of RBC 
proteins should be considered in laboratory practice. 
The patient in this study was treated with phenytoin, which was able to control 
his GTC convulsion (Fujii et al., 2006). Phenytoin has been reported to increase 
GLUTl gene expres:,ion in human skin fibroblast (Wong et al., 2005), which may 
account for the improvement seen in this patient after the treatment. Knowing more 
about the interaction between antiepileptic drugs and Glutl function and expression will 
certainly benefit GlutlDS patients. 
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Chapter 3 
Pathogenicity Studies of GLUTl Mutations 
After the identification of the novel mutation in the GlutlDS patient, the 
pathogenicity of this mutation is further studied in vitro using the Chinese Hamster 
Ovary (CHO-Kl) cell as a mammalian testing model. A C-terminal GFP-fusion 
construct was used in this study, since the Glutl-GFP system has been reported to be 
functional in the CHO cell system (Zaslavskaia et al., 2001; Levine et al., 2002). Wild 
type and mutant Glutl-GFP fusion proteins were expressed in CHO-Kl cells and the 
activity and subcellular localization of Glutl-GFP in the transfected cell lines were 
investigated. Two mutants, 1034-1035Insl2 and G91D were constructed. G91D 
mutant is previously confirmed to be a pathogenic GLUTl mutation (Klepper et al., 
2001a) and hence, was used to validate the effectiveness of our expression system in 
reporting the functional defect of Glutl. 
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3.1 Materials 
3.1.1 Construction of Glutl-Encoding Vectors 
3.1.1.1 Mammalian Expression Vector 
The pEGFP-Nl expression vector was purchased from Clonetech (Palo Alto, 
CA, USA). It encodes a red-shifted variant of wild-type Green Fluorescence Protein 
(GFP), which has been optimized for brighter fluorescence and higher expression in 
mammalian cells. Fi sioii to the N-terminus of Enhanced GFP retains the fluorescent 
properties of the native protein, allowing the localization of the fusion protein to be 
observed in vitro. 
3.1.1.2 Site-Directed Mutagenesis 
3.1.1.2.1 Q u i c k c h a n g e T M Site-Directed Mutagenesis Kit 
It was purchased from Stratagene (La Jolla，CA, USA). 
3.1.1.2.2 Primer Pairs 
The oligonucleotide primers were designed on the basis of the published 
sequence of the human GLUTl gene with the desired mutation at the middle and 
synthesized by Invitrogen Life Technologies (Carlsbad, California, USA). The primer 
pairs were handled in the same way as mentioned in Section 2.1.6.2. 
3.1.1.3 Bacterial Culture Medium 
3.1.1.3.1 Luria Broth (LB) Medium and LB Agar 
Both items were purchased from USB (Swampscott, MA, USA). 
3.1.1.3.2 Kanamycin Sulfate 
A stock (25 mg/ml) of kanamycin sulfate (Amersham, GE Healthcare, 
Buckinghamshire, England) was prepared in double distilled water. The working 
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solution (50 ^il/ml) was prepared by diluting the stock solution 500 fold in LB medium 
or LB agar before use. The stock solution was stored at -20°C. 
3.1.1.4 Plasmid Purification Kit 
Plasmids from overnight bacterial culture were purified by the Wizard® Plus 
SV Minipreps DNA Purification System (Promega, Madison, WI, USA) 
3.1.2 Cell Line 
3.1.2.1 Chinese Hamster Ovary Cells (CHO-Kl) 
CHO-Kl (ATCC CCL-61) was purchased from the ATCC, USA. It is a 
Chinese Hamster cell line, which was derived from a biopsy of an ovary of an adult 
Chinese hamster in 1957. 
3.1.3 Cell Culture Media, Buffers and Other Reagents 
3.1.3.1 Cell Culture Media 
3.1.3.1.1 Dulbecco's Modified Eagle's Medium (D-MEM), Powder (High 
Glucose) 
The powder form of high glucose D-MEM medium (Gibco BRL Life 
Technologies, Inc., Carlsbad, CA, USA), which was supplemented with 4.5 g/L D-
glucose, 4 mM L-glutamine, 110 mg/L sodium pyruvate, and 4 mg/L pyridoxine HQ, 
was used for the preparation of culture medium, for sub-culturing the CHO-Kl cell 
lines. The powder was dissolved in double distilled water and buffered with 3.7 g/L of 
sodium bicarbonate (NaHCO.^) (Sigma, St. Louis, MO, USA). The pH value of the 
medium was adjusted to 7.2-7.4 by 6 N HCl (Sigma, St. Louis, MO, USA) and the 
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medium was then sterilized by passing through a 0.22 jum filter (Millipore Billerica, 
Mass, USA) and stored at 4°C until use. 
3.1.3.2 Media Supplement 
3.1.3.2.1 Fetal Bovine Serum (FBS) 
FBS was purchased from Gibco BRL Life Technologies, Inc. (Carlsbad, CA, 
USA) and was stored as 50 ml aliquots in sterile centrifuge tubes at -20°C until use. 
The aliquots were added to D-MEM medium to give a final concentration of 10% FBS 
in the medium. 
3.1.3.2.2 Antibiotics Mixture Solution 
A lOOX stocr： of Penicillin-Streptomycin (PS) antibiotics mixture containing 
10,000 units/ml of penicillin G sodium and 10,000 fxg/ml of streptomycin sulfate in 
0.85% saline was purchased from Gibco BRL Life Technologies, Inc. (Carlsbad, CA, 
USA). It was stored as 10 ml aliquots in sterile centrifuge tubes at -20°C. The lOOX 
stock solution was added to D-MEM medium to give 1% antibiotics for preventing any 
possible contamination of the cell culture. 
3.1.3.3 Phosphate-Buffered Saline (PBS) 
All chemicals for lOX PBS preparation were purchased from Sigma (St. Louis， 
MO, USA). Stock P8S solution (lOX) containing 1370 mM sodium chloride (NaCl), 
27 mM potassium chloride (KCl), 100 mM dibasic sodium phosphate (NazHPO*) and 
20 mM monobasic potassium phosphate (KH2PO4) was prepared in one liter of double 
distilled water with pH calibrated to 7.4 by 6 N HCl or 2 M NaOH. A working PBS 
solution (IX) was prepared by diluting 1 part of lOX stock solution with 9 parts of 
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double distilled water and then autoclaved at 121°C for 20 minutes for sterilization. It 
was stored at 4°C until use. 
3.1.3.4 Trypsin-EDTA Solution 
2+ 2+ 
Trypsin-EDTA solution (without Ca and Mg ) was purchased from Gibco 
BRL Life Technologies, Inc. (Carlsbad, CA, USA). It contained 0.05% (w/v) trypsin 
and 0.53 mM EDTA -tetrasodium in Hank's Balanced Salt Solution. It was stored at -
20°C as 50 ml aliquots until use. 
3.1.4 Cell Culture Wares 
Glass wares used for sub-culture and experiments, including 100 mm dishes, 
multi-well plates and centrifuge tubes were all purchased from Greiner (Kremsmiinster, 
Austria) unless otherwise indicated. 
3.1.5 Reagents for Transfection 
3.1.5.1 Transfection Reagent 
L i p o f e c t a m i n e T M 2000 Reagent was purchased from Invitrogen, Life 
Technologies (Carlsbad, CA, USA) for the transfection of plasmids into CHO-Kl cells. 
The reagent was kept at 4°C. 
3.1.5.2 Selection Antibiotics 
G418 sulfate cell culture tested powder was purchased from Calbiochem (San 
Diego, CA, USA) for the selection of eukaryotic expression vectors carry the bacterial 
neoVkan^ genes. Stock solution of G418 with a concentration of 50 mg/ml was prepared 
in IX PBS and stored at 4°C. 
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3.1.6 Reagents for Protein Determination and Western Blot Analysis 
3.1.6.1 Mouse Anti-GFP Monoclonal Antibody 
Anti-GFP antibody, which is a mixture of two mouse monoclonal antibodies, 
was purchased from Roche Molecular Biochemicals (Basel, Switzerland). The antibody 
stock solution was prepared by dissolving the lyophilized anti-GFP in 500 |al of distilled 
water to produce an antibody concentration of 0.4 mg/ml. The reconstituted antibody 
was stored as small aliquots at -2()°C. 
3.1.6.2 Mouse Anti-Glyceraldehyde-3-PDH (GAPDH) Monoclonal Antibody 
Anti-GAPDH antibody was purchased from Chemicon International Inc. 
(Temecula, California, USA). The concentration of antibody stock solution was 1 
mg/ml and was stored as small aliquots at 4°C. 
3.1.6.3 Protein Assay Dye Reagent 
The dye was purchased from Bio-Rad Laboratories (Hercules, CA, USA). The 
protein assay, based on the Bradford dye-binding procedure, is a simple colorimetric 
assay for measuring total protein concentration. 
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3.1.7 Consumables for Confocal Microscopy 
3.1.7.1 Microscope Slides 
It was purchased from Fisher Scientific Limited (Pittsburgh, PA, USA). 
3.1.7.2 Leica Confocal Microscope TCS NT 
Leica Confocal microscope TCS NT was purchased from Leica Microsystems 
(Heidelberg, Germany). 
3.1.8 Reagents and Buffers for Flow Cytometry 
3.1.8.1 FACS Flow Shealth Fluid 
The shealth fluid is a ready-to-use balanced electrolyte solution containing 
sodium chloride, potassium chloride, disodium EDTA, sodium fluoride and anti-
microbial agent, was purchased from the Becton Dickinson International (Franklin 
Lakes, NJ, USA) and stored at room temperature. 
3.1.9 Reagents for 2-DOG Uptake in CHO-Kl Cells 
3.1.9.1 Krebs-Ringer Phosphate Buffer (KRPB) 
KRPB solution was prepared by mixing 130 mM NaCl, 5 mM KCl, 1 3 mM 
CaCl2, 1.3 mM MgS04, and 10 mM NazHPO* (Sigma, St. Louis, MO, USA) in 500 ml 
of double distilled water with pH calibrated to 7.4 by 6 N HCl or 2 M NaOH. It was 
stored at 4°C until use. 
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3.1.9.2 2-Deoxy-D-GIucose (2-DOG) 
2-DOG was purchased from Sigma (St. Louis, MO, USA). The powder was 
dissolved in KRPB solution as a stock solution of 10 mM and stored at 4°C until use. 
3.1.9.3 2-Deoxy-D-[l-^H]-Glucose (^H-2-DOG) 
The stock s ,lution (14 Ci/mmol) was purchased from Amersham (GE 
Healthcare, Buckinghamshire, England) and stored at 4°C. 
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3.2 Methods 
3.2.1 Cell Culture Methodology 
CHO-Kl cells were maintained in high glucose D-MEM containing 3.7 g/L 
NaHC03 supplemented with 10% FBS and 1 % PS. Cells were kept at 37°C under a 
humidified 5% CO2 atmosphere. Medium of the cell line was changed every 2-3 days 
and subcultured one?, to twice a week depending on the cell density. Cells were 
maintained between the and passages for experiments. 
For the subculture procedures, growth medium was first aspirated and the 
adherent cells were rinsed once with pre-warmed IX PBS before mild trypsinization 
with 1 ml of EDTA-trypsin solution at 3 7 � C for 1-2 minutes. Then 10 ml of fresh 
medium was added to stop trypsinization when all the cells were detached from the 
culture dish. The detached cells were collected by centrifuging at 201 x g for 3 minutes 
at 25°C. Cell pellet was then re-suspended in fresh medium and appropriate aliquots of 
cell suspension were transferred into a new culture dish with 10 ml of fresh medium. 
For long-term storage of the cell line, cells were first allowed to grow until 80% 
confluence and trypsinized as described previously. Then the cell pellet was re-
suspended in 1 ml of fresh medium. After that the cell suspension was dispensed into 
pre-labeled cryogenic vial (Nalgene, NY, USA) with 10% cryoprotectant dimethyl 
sulfoxide (v/v) (Sigma, St. Louis, MO, USA). The vials were placed in a Nalgene 
freezing container (Sigma, St. Louis, MO, USA) at -80°C freezer to achieve l°C/minute 
cooling rate. After an overnight incubation, the vials were transferred to liquid nitrogen 
freezer. 
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3.2.2 Constructioa of GLUTl Mutants 
The mutant constructs were generated from the wild type GLUTl plasmid 
(constructed by our previous labmate Miss Hei Yi Wong) using RNA extracted from a 
normal fibroblast cell line as template by Q u i c k c h a n g e T M site-directed mutagenesis kit 
following the manufacturer's instruction. For each construct, 72 ng of double-stranded 
wild type plasmid was subjected to PCR amplification by TurhoPfu DNA polymerase 
using a pair of primers containing the mutation in the middle and reverse 
complementary to each other (Table 3.2.1). The components in the PCR reaction are 
shown in Table 3.2.2. The plasmid was initially denatured for 30 seconds at 95°C, 
followed by 14 cycles of 30-second denaturation at 95°C, 1-minute of annealing at 
52°C and 14-minute of extension at 68°C. After temperature cycling, the reaction 
mixture was subjected to Dpn I digestion (10 U/reaction) for the elimination of parental 
dam-methylated wild type template. The entire digested product was transformed into 
competent E.coli strain DH5a following the procedures mentioned in Section 3.2.2.1 
and plasmids were purified by the Wizard® Plus SV Minipreps DNA Purification 
System. The nucleotide sequences of the mutant clones were confirmed by DNA 
sequencing performed by Macrogen Inc. (Seoul, Korea). 
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Table 3.2.1 Primer sequences for different mutant constructs prepared from 
Q u i c k c h a n g e T M site-directed mutagenesis k i t 
Mutant Primer set 
1034-1035Insl2 Forward: 
.5 ' -CCC AGC AGC TGT CTC AGC AGC TGT CTG GCA 
TCA AGC CTG-3' 
Reverse: 
5，-CAG C G T T G A T G C C A G A C A G C T G C T G A G A C A 
GCT GCT GGG-3, 
G91D Forward: 
5'-CTT TTC GTT AAC CGC TTT CAC CGG CGG AAT TCA 
ATG C-3’ 
Reverse: 
5,-GCA TTG AAT TCC GCC GGT CAA AGC GGT TAA 
CGAAAAG-3, 
Table 3.2.2 Components in the PCR amplification of Quickchange^"^ site-directed 
mutagenesis 
Component Volume (i^ i) 
lOX PCR reaction buffer 5 
10 i^ iM primer F 1 
10 fiM primer R 1 
dNTP mix 1 
Wild type plasmid (0.331 |ag/|al) 0.22 
Autoclaved H2O 40.78 
TurboPfu polymerase 1 
Total: 50 
3.2.2.1 Transformation 
The Dpn I-digested PCR product was transformed into E. coli DH5a strain by 
transient period of heat shock. The entire digested product was first mixed with 200 |il 
of competent cells anJ incubated on ice for 15 minutes allowing the plasmids to attach 
on the competent cells. The mixture was then introduced to a heat shock period of 2 
minutes at 42°C in which the extracellular plasmids was rapidly influx into the 
bacterium. After the heat shock period, the mixture was stood on ice for another 2 
minutes before recovery. Eight hundred microliters of nonselective LB medium was 
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added to the bacterium and the suspension mixture was allowed to recover at 37°C for 
30 minutes with shaking. This step was necessary to ensure full viability of the 
transformants. After the recovery period, the transformed bacteria were plated onto LB 
agar plate supplanted with 25 | L i l / m l of kanamycin and incubated in a 37°C incubator for 
18-24 hours. Single bacterial colony was then picked and inoculated in LB broth, with 
25 |il/ml of kanamycr-i for another 18-24 hours for plasmid production. 
3.2.2.2 Purification of Plasmid DNA 
Plasmids were purified from bacteria using Wizard® Plus SV Minipreps DNA 
Purification System (Promega, Madison, WI, USA). Three milliliters of overnight 
culture was transferred to a 1.5 ml microcentrifuge tube for centrifugation at 9300 x g 
for 15 seconds and the LB medium was discarded. Two hundred and fifty microliters of 
Resuspension Soluticn was added to resuspend the cell pellet, followed by the addition 
of 250 [x\ of Cell Lysis Solution with mixing. The lysate was then mixed with lOfxl of 
Alkaline Protease Solution and the mixture was incubated for 5 minutes at room 
temperature. After the incubation, 350 |il of Neutralization Solution was added to the 
mixture and mixed immediately. Subsequently, the lysate was centrifuged at 14000 x g 
for 10 minutes at room temperature. The supernatant was then transferred to a Spin 
Column inserted into a 2 ml Collection Tube and spun at 14000 x g for 1 minute. The 
flow-through was discarded and 750 of Column Wash Solution was added to the 
column and spun at ] 4000 x g for 1 minute. Again the flow-through was discarded and 
another 250 |LI1 of Column Wash Solution was added to the column and spun at 14000 x 
g for 2 minutes. The Spin Column was then transferred to a new 1.5 ml microcentrifuge 
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tube and plasmids were eluted by adding 50 |LI1 of Nuclease-Free Water to the column 
and spun at 14000 x g for 1 minute at room temperature. The plasmids were stored at -
20°C until use. The plasmids were subjected to sequencing analysis by Macrogen Inc., 
(Seoul, Korea) to confirm the presence of the mutation. 
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3.2.3 Establishment of Wild Type and Mutant Glutl Expressing Cell 
Lines 
3.2.3.1 Transfection 
CHO-Kl cell was used as a mammalian model to conduct in vitro glucose 
uptake assay. The wild type and mutant-expressing cell lines were generated by 
transfecting CHO-Kl cells with the corresponding plasmids in which the target cDNA 
was expressed from the cytomegalovirus immediate-early promoter. Control cell lines 
were also generated in parallel by transfecting the parental cells with pEGFP-Nl vector 
alone. Transfection was performed using Lipofectamine™ 2000 kit following the 
manufacturer's instruction. Briefly, 5 x 10''' cells/well were seeded in a 6-well plate and 
allowed overnight attachment. For each well of transfection, 1 |ag of plasmid and 6 
of L i p o f e c t a m i n e T M 2000 reagent were diluted in 200 |LI1 of plain high glucose D-MEM 
separately and mixed gently. After 5 minutes of incubation at room temperature, the 
diluted plasmid and Lipofectamine™ 2000 reagent were mixed and allowed to stand for 
20 minutes at room temperature. Then growth media in the 6-well plate were aspirated 
and replaced with 1.5 ml of high glucose D-MED/well with 400 |al of Lipofectamine™ 
2000-DNA complex. After 5-hour incubation at 37°C, the L i p o f e c t a m i n e T M 2000-DNA 
complex was removed and replaced with fresh growth D-MEM. The cells were then 
maintained overnight at a 3TC incubator. 
3.2.3.2 Generation of Stable Cell Lines 
Cells were passed at a 1:10 ratio into a 12 well plate and allowed to grow at 37 
°C overnight. G418 sulfate- (1 mg/ml) containing-growth media was added into the 
wells for selection on the following day. The medium was changed every other day 
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until 90% confluence, and then the G418 resistant cells were harvested with trypsin and 
transferred to a 100 mm dish. After selection, cells were maintained in growth media 
supplemented with G418 sulfate (1 mg/ml). Cells between passage and were 
used for experimental studies with the removal of G418 from the culture medium. 
Three individual tran^fections were performed for each mutant construct as well as the 
control. Long-term storage of cell lines was done by cryo-preservation, cells were kept 
as frozen stock in freezing medium containing growth medium and 10% DMSO and 
stored in liquid nitrogen. At least three stock vials of every clone from each 
transfection were kept. 
3.2.4 Protein Expression Study 
3.2.4.1 Protein Extraction 
Forty-eight hours after transfection, the cells were washed twice with 1 ml of IX 
PBS and incubated with 0.5 ml of trypsin for 1 minute at 37�C. Then 1 ml of IX PBS 
was added and the trypsinized cells were transferred to a 1.5 ml microcentrifuge tube 
and centrifuged at 201 x g for 3 minutes at room temperature. The cell pellet was then 
washed twice with IX PBS and centrifuged at 201 x g for 3 minutes at room 
temperature. Afterwards, the pellet was re-suspended in 200 |LI1 of IX PBS and 
subjected to sonication. The cell suspension was sonicated 3 times for 10 minutes on 
ice using Branson Sonifier ultrasonic liquid processors (Danbury, CT, USA). The cell 
lysates were kept at -20°C for long- term storage. 
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3.2.4.2 Quantification of Proteins 
Protein content of the cell lysate was estimated by Bio-Rad protein assay kit 
with BSA as standard. BSA solution at concentration of 0.2 mg/ml, 0.4 mg/ml, 0.6 
mg/ml, 0.8 mg/ml and 1 mg/ml were prepared with IX PBS in duplicate with 1 mg/ml 
BSA stock solution. The concentration of samples was quantified 
spectrophotometrically by BioPhotometer (Eppendorf，Hamburg, Germany) in 
wavelength 595 nm. 
3.2.4.3 Western Blot Analysis 
Western blot analysis was carried out to confirm the expression of plasmids 
encoding wild type and mutant GLUTl clones. A 12% SDS-polyacrylamide gel was 
prepared as indicted in Table 3.2.3. Twenty micrograms of protein samples were mixed 
with 4X SDS gel loading buffer and incubated at room temperature for 30 minutes 
before subjecting to electrophoresis in 12% SDS-polyacrylamide minigel (Sun et al., 
2001). The gel was run under constant voltage of 100 volts for 2 hours. 
Table 3.2.3 Composi:ion of 12% SDS-polyacrylamide gel 
Reagent 5% Stacking Gel 12% Running Gel 
30% Acrylamide Stock 0.825 ml 2 ml 
Stacking Gel Buffer 1.25 ml -
Running Gel Buffer - 1.25 ml 
Distillated Water 2.875 ml 1.7ml 
10% APS 50 1^1 50 iLil 
TEMED 3.3 |al 3.3 
The proteins on the gel were then electroblotted onto the PVDF membrane at 
100 volts for 2 hours as described in Section 2.2.4.3. After the transfer, the membrane 
with transferred protf ins was rinsed with TBS-T. The membrane was then blocked with 
TBS-T containing 5% skimmed milk for 1 hour at room temperature, following by 
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incubation with anti GFP antibody at 1:4000 dilutions in 5% skimmed milk at 4°C 
overnight. After blotting with anti-GFP，the membrane was washed 3 times with TBS-
T for 5 minutes. After washing, the membrane was incubated with horseradish 
peroxidase-linked secondary antibody at 1:6000 dilutions in 5% skimmed milk for 1 
hour at room temperature. Then the membrane was washed with TBS-T for 5 minutes 3 
times. After washing, the membrane was subjected to ECL assay to detect the 
expression level. In addition, the membrane was probed with anti-GAPDH antibody, 
which served as a control protein. After blocking with 5% skimmed milk for 1 hour, 
the membrane was .^lotted with anti-GAPDH antibody at 1:20000 dilutions in 5% 
skimmed milk at room temperature. After 1 hour of incubation, the membrane was then 
washed and probed with secondary antibody identically to that of GFP, followed by 
ECL assay detection. 
3.2.4.4 ECLTM Assay 
The procedures were identical to the description in Section 2.2.4.4. The film 
was allowed to expose in the dark for 15 minutes before development. 
3.2.5 2-DOG Inflinx Assay in CHO-Kl Cells 
3.2.5.1 2-DOG Influx into CHO-Kl 
Stable CHO-Kl cell lines expressing vector control, wild type and 2 different 
mutants were used to perform uptake and kinetic study as previously described 
(Muraoka et al； 1995). Briefly, 1 x lO? cells/well were seeded in 24-well plate and 
cultured for 2 days. Then cells were washed 3 times with 1 ml/well of IX PBS and 
once with 0.5 ml/well of KRPB solution. Then cells were incubated with 0.5 ml/well of 
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KRPB solution for 20 minutes at 37°C. Two hundred microliters of H/C mixture 
containing 1 ).iCi/ml of ^H-2-DOG, 0.1 mM of 2-DOG in KRPB solution was added. 
The uptake and kinetic reactions were allowed to proceed for 5 minutes and 1 minute at 
37°C, respectively. 'i he reaction was stopped by adding 1 ml/well of ice-cold IX PBS 
containing 0.3 mM phloretin. Each well was washed twice with the same ice-cold stop 
solution. The whole washing procedure was performed on ice to prevent the efflux of 
2-DOG. After the washing step, 500 | L i l / w e l l of 0.1% SDS solution was added to lyse 
the cells. Four hundred microliters of the lysate was then mixed with 4 ml/sample of 
OptiPhase HiSafe 2 scintillation cocktail and subjected to radioactivity counting by a 
Beckman LS 6500 multi-purpose scintillation counter (Beckman Coulter, Inc., Fullerton, 
California, USA). 
3.2.5.2 Quantification of Protein 
Protein content of the cell lysate was quantified by the Bio-Rad protein assay as 
mentioned in Section 3.2.4.2. BSA standard was used and diluted by lysis buffer 
solution. The amount of 2-DOG influx was normalized by the cell protein 
concentration. 
3.2.5.3 Flow Cytometric Analysis of Transfection and Expression Efficiency 
GFP-expressirig cells were seeded in 6-well plates at a density of 1 x 10() 
cells/well and cultured for 2 days. After trypsinization, cells were then transferred to a 
1.5 ml microcentrifuge tube and centrifuged at 201 x g for 3 minutes at room 
temperature. The cell pellet was then washed twice with IX PBS. Afterwards, the 
pellet was resuspended in 1 ml of ice-cold IX PBS and subjected to counting for 
fluorescence intensity with a fluorescence-activated cell sorter (Becton Dickinson 
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FACSort) equipped with an argon laser for emitting wavelength 535 ± 15 nm and 
operated by the CellQuest software. A minimum of 10,000 events was acquired for 
each determination. The percentage of fluorescent cells expressing GFP was calculated 
by the WINMDI version 2.8 software (J. Trotter; Scripps Research Institute, La Jolla, 
CA). Transfection and expression efficiency was presented as the percentage of GFP 
expressing cells divided by the total cell number and was routinely observed to be 
around 40% for all transfected cell lines. 
3.2.6 Confocal Microscopy Studies on Glutl Cellular Localization 
Wild type and mutant Glutl-expressing CHO-Kl cells were seeded at the 
density of 1 x 10'^  cells/well and were grown on a sterile cover slip (Fisher Scientific, 
Pittsburgh, PA, USA). The cover slips were placed in the well of a 6-well plate and 
immersed in 1.5 ml of fresh growth medium. After an overnight incubation at 37°C，the 
coverslips with the cells were mounted onto a metal holder of a perfusion chamber 
(Model PH-2, Warner Instrument Corporation) were observed under a laser scanning 




All experiments were repeated at least three times with similar results obtained. 
Results shown represent the pooled values of three to four experiments each in triplicate 
setup. Each data point is expressed as mean 土 S.E. (standard error) unless otherwise 




3.3.1 Molecular Analysis of 1034-1035Insl2 Mutation 
After the diagnosis of GlutlDS patient mentioned in Chapter 2，the identified 
mutation was further studied in vitro to characterize its pathogenicity. The mutation 
was first introduced into the wild type GLUTl gene and the clone baring the mutated 
GLUTl gene was subjected to DNA sequencing analysis. The sequencing result of the 
mutants confirmed the mutations in the GLUTl gene. An extra 12-nt CAG CAG CTG 
TCT sequence was inserted in between nucleotide 1034 and 1035 of GLUTl gene in 
1034-10351ns 12 mutant (Fig. 3.3.1 B). For the G91D mutant a missense mutation 
(G->A) at nucleotide position 272 was confirmed (Fig. 3.3.1 D). 
A) 
560 570 580 
、CAGCAGCTGTCTGGCATCAACGCTG 
Q Q L S 
I k M y M 
B) 
550 560 570 
:CAGCAGCTGTCTCAGCAGCTGTCTGGC 
Q Q L S Q Q L S 
W f t j y w M 
91 
C) D) 
70 F G R 370 F D R 
>CCGCT TTGGCCGGCGG . 2CGCT T TGH^CGGCGG . 
, 1 辦 III 請隱 i f f i f n T w w i 
If I 『 '1 nU f\ ILl Ay iiil H L 
Figure 3.3.1 Automated DNA sequencing for confirmation of the mutant GLUTl. 
A) Normal sequence of GLUTl gene between nucleotide 1023 and 1046, B) Insertion 
of a 12-nucleotide sequence (CAG CAG CTG TCT) between nucleotide sequence 1034 
and 1035. C) Normal GLUTl gene sequence at nucleotide position 272, D) The boxed 
nucleotides indicated the site of mutation, a G to A mutation at position 272 resulted in 
a glycine to glutamine transition in protein sequence position 91. 
3.3.2 Expression of the Wild Type and Mutant GFP-Glutl Fusion Proteins 
The vectors containing the mutations were then transfected into CHO-Kl cells 
and the expressions of the mutant Glutl proteins were examined by western blot. By 
using RT-PCR it was found that GLUT4 was highly expressed in non-transfected CHO-
Kl cells whereas nearly no GLUTl expression was observed (Jessie Sun and WT 
Cheung. Department of Biochemistry, The Chinese University of Hong Kong, 
unpublished data, data not shown). Thus endogenous Glutl mediated glucose transport 
in non-transfected CHO-Kl cells should be very low. In Figure 3.3.2，both the wild 
type and mutant Glutl proteins were expressed in the CHO-Kl cell model. The Glutl-
GFP fusion proteins were observed as a band at 82 kDa, which was the combined 
molecular weight of the Glutl (55 kDa) and GFP proteins (27 kDa). A 27 kDa-band 
was present in the lane of pEGFP-Nl vector control. This validated the affinity of the 
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anti-GFP antibody. No bands were found in the lane of non-transfected CHO-Kl cells 
as anticipated, because this sample served as a negative control. GAPDH, a glycolytic 
enzyme, which is present in almost all tissues, served as a loading control in the 
experiment. 
Apart from the expression of the target proteins, similar transfection and 
expression efficiency among different cell lines were confirmed to ensure the obtained 
results were reliable and comparable. The transfection/expression efficiency of CHO-
Kl cells were quantified using flow cytometry, by which the green fluorescence signals 
in the cells were measured. The percentage of transfection/expression efficiency of the 
wild type- and mutant-expressing cell lines were indicated in Table 3.3.1 and the values 
were comparable. 
圓 2 
95 kDa — H ^ ^ R ^ ^ ^ ^ S H 
^ I ^ J U P I I I ^ Glutl-GFP 
54 kDa — 
37 kDa — 
29 kPa GFP 
GAPDH 
Figure 3.3.2 Similar expression of wild type and mutant Glutl-GFP fusion protein 
in CHO-Kl cells. Twenty micrograms of CHO-Kl whole cell lysates were subjected 
to 12% SDS-polyacrylamide gel electrophoresis and probed with antibodies specific for 
GFP or GAPDH. Lane 1) non-transfected CHO-Kl，lane 2) GFP vector control, lane 3) 
wild type Glutl, lane 4) 1034-1035Insl2 mutant and 5) G91D mutant. Results shown 
are from a single experiment representative of the results of three independent 
experiments. 
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Table 3.3.1 Flow cytometry analysis of transfection and expression efficiency in 
transfected cells. F'')ch data point was the average of three separate experiments and 
presented as mean 土 S.E. 
Cell line Transfection/expression efficiency 
(% total count) 
Wild type Glutl 40.35 ± 1.35 
1034-1035Insl2 38.92 土 3.17 
G91D 38.39 土 5.06 
The Glutl-GFP expressing CHO-Kl cells were observed under confocal 
microscopy and the localizations of the fusion proteins were visualized as green 
fluorescence signals -n the cells. In the vector control, the green fluorescence was 
distributed evenly throughout the cells in both the nucleus and the cytoplasm (Fig. 3.3.3 
A). However, in the CHO-Kl cells expressing the wild type (Fig. 3.3.3 B) or the 
mutant Glutl fusion proteins (Fig 3.3.3 C and D), the green fluorescence signals were 
localized along the plasma membrane, which was the destination of Glutl protein. This 
observation suggested that membrane targeting ability of Glutl protein was not blocked 
by the 2 mutations studied. Both mutated Glutl proteins localized along the plasma 
membrane similar to the wild type Glutl protein. Clusters of green fluorescence singles 
observed in the cells expressing Glutl-GFP fusion protein, suggesting that the proteins 
were undergoing post-translation modification at the endoplasmic reticulum or the golgi 
bodies. 
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Figure 3.3.3. Confocal microscopy analysis of cellular localization of Glutl-GFP 
fusion proteins in CHO-Kl cells. Living CHO-Kl cells were subjected to confocal 
microscopy analysis. A) GFP vector control, B) wild type Glutl, C) 1034-1035Insl2 
mutant and D) G91D mutant. For GFP observation, excitation wavelength of 488 nm 
and an emission band pass filter 530 士 30 nm were used. Cells were magnified 2560x. 
Results shown were collected from two separated experiments. Arrowheads indicate 
the profiles of cell membrane while ‘*，represents intracellular aggregates. 
3.3.3 Functional Analysis of the 1034-1035Insl2 Mutant 
The glucose uptake activity of Glutl-GFP fusion proteins was evaluated by 2-
DOG uptake assay. The 2-DOG uptake activities at 37°C of both mutants were 
significantly lower than that of the wild type Glutl-GFP fusion protein by 60% to 70% 
(Fig. 3.3.4 A). The result of 1034-10351ns 12 mutant was not consistent with the one 
obtained from erythrocyte study (Chapter 2, Fig 2.3.4)，in which the assay was 
conducted at 4°C. Therefore, another 2-DOG influx assay was performed at 4°C in 
order to mimic the experimental condition in the erythrocyte study (Fig. 3.3.4 B). The 
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glucose uptake activity of the CHO-Kl cells at 4°C was even lower than that at 37°C. 
The effect of temperature will be discussed later in the Discussions section. 
A) B) 
= ^ « 150. I 150 1 
I 12� T I 12° - -r 
^ 90 r H 2 90 r ^ 
I 60 * * £ 60- * 
I 30 ^ r 1 * •• 
§ 0 - J ~ U - J I r i , I- 0 _ L I 丄 I r - ^ ， 
9 wild type 1034- G91D mutant o .gQ J wild type Glutl 1034- G91D mutant 
Glutl 10351ns 12 § 1035lns12 
mutant mutant 
Cell line 
Cell line Figure 3.3.4 Impaired 2-DOG uptake activity of mutants was determined at 
different temperatures. 2-DOG uptake was measured after a 5-minute incubation with 
0.1 mM of 2-DOG (3 determinations/data point). A) Glucose transport activity 
determined at 37°C. B) Glucose activity determined at 4°C. The uptake activity of 
mutant Glutl was calculated as the percentage of the wild type Glutl after subtracting 
the vector control value. Each data point represents the mean of 3 independent 
experiments in triplicate set up. * Significant difference between wild type Glutl and 
mutant Glutl expressing cell lines. 
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3.4 Discussion 
The G91D mutant, which served as a control for the CHO-Kl experimental 
setup was previously studied in Xenopus oocytes (Klepper et al., 2001a). The results 
observed in the Xenopus oocytes model could be reproduce in CHO-Kl model. The 
results of pathogenic studies from both models are summarized in Table 3.4.1 (Klepper 
et al., 200la). These results support that CHO-Kl model is another alternative for 
studying the GLUTl gene mutation. 
Table 3.4.1 Comparison of Glutl pathogenicity studies in Xenopus oocytes and 
mammalian CHO-Kl cell models. 
Xenopus oocytes Model Mammalian CHO-Kl Model 
Membrane Glucose Membrane Glucose 
Expression Transporter Expression Transporter 
(% Control) (% Control) 
G91D ^ ^ NC ^ 
Key: 'NC'= no change in the indicated parameter and 'Control'= wild type Glutl 
control 
Upon collecting the results in the CHO-Kl cell studies, several discrepancies 
from erythrocyte studies of the novel insertion mutation were observed. In the western 
blot analysis, there was no extra lower molecular weight band observed in 1034-
1035Insl2 expressed CHO-Kl cell lysate (Fig. 3.3.2)，which was previously seen in 
erythrocyte study (Fig 2.3.6). As mentioned in the previous chapter, this insertion 
mutation may encode for a protein product, which is more susceptible to 
deglycosylation and results in the extra band in western blot analysis of the patient 
erythrocytes. However, in the CHO-Kl cells the post-translational modification may 
differ from the human, the expression of the 1()34-I0351nsl2 Glutl protein produced a 
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glycosylated form of Glutl and was detected as a GFP fusion protein with the same 
molecular weight (82 kDa) as the wild type Glutl fusion protein. 
The glucose uptake activity of the 1034-1035Insl2 mutant reduced in CHO-Kl 
cell study which was not observed in erythrocyte study. Such difference might be due 
to a homogenous mutant GLUTl gene was introduced into the CHO-Kl cells, hence all 
the expressed Glutl proteins were mutated. However in the erythrocytes it is predicted 
that only 50% of the expressed Glutl proteins were mutated since the patient carries a 
heterozygous mutation. The Glutl protein functions as a tetramer, it is possible that in 
the case of heterogeneous mutation, the normal Glutl expressed from wild type GLUTl 
allele might still be functional that can rescue the activity of the tetramer. However, in 
the case of homogen ous mutation expressed in the CHO-Kl cells, all expressed Glutl 
proteins are defective and this might result in the reduction of the uptake activity of the 
tetramer. 
The discrepancy of glucose influx results obtained in CHO-Kl cells and 
erythrocytes may also be due to somatic mosaicism of the mutation. Somatic 
mosaicism of mutations in disease-causing genes have been reported in several studies, 
examples including many skin disorders and hemophilia A (Leuer et al., 2001). 
Somatic mosaicism is attributed to two stem cell lines as a result of postzygotic 
mutation during early embryogenesis. The ratio of cells that carried the mutation may 
vary in the two tissues, the ratio of erythrocytes carrying mutation maybe lower than 
cells in the BBB, therefore, no influx defect was observed in the Glutl protein in the 
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erythrocytes. However, this mutation may be important for glucose efflux in the Glutl 
protein so, even a low ratio of erythrocytes carrying the mutation can still result in 
efflux defect. The 2-DOG influx results obtained from CHO-Kl cells may still explain 
the pathogenicity of the mutation. Since homogenous mutation in CHO-Kl cells is like 
having a high ratio of cells carrying the mutation, which then causes an influx defect on 
the Glutl protein. The 1034-1035Insl2 mutation caused a glucose efflux reduction of 
Glutl proteins in the erythrocytes (Fig. 2.3.5), the insertion mutation is predicted to 
encode for an extra QQLS motif, which is highly conserved among the class I Glut 
family and the glutamine residues in the motif are important for glucose binding (Mori 
et al” 1994). This mutation may alter the conformation of the Glutl protein, hence 
affect its efflux activity. Since the Glutl protein is responsible for both the uptake and 
efflux of glucose in the brain, change of either one of its activities will affect glucose 
homeostasis in the brain, which may result in GlutlDS-associated symptoms like, 
seizures. The effect of the 1034-1035Insl2 mutant on glucose efflux in CHO-Kl cells 
will also be investigated in the future in order to elucidate its effect on Glutl efflux 
activity. The pathogenicity of 1034-1035Insl2 mutation maybe a combination of both 
influx and efflux defects of the Glutl protein. 
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Chapter 4 
GLUTl Promoter Study 
Since the successful cloning and characterization of the human GLUTl gene in 
1988 (Fukumato et al” 1988a)，the coding region of GLUTl gene is studied extensively. 
Since the identification of GlutlDS in 1991 (De Vivo et al., 1991) increasing number of 
mutations has been reported in the gene especially in the coding region. So far no 
GlutlDS-associated mutation is found in the 5’-upstream region of GLUTl gene. In 
order to investigate any linkage between GLUTl gene regulation, and the GlutlDS, the 
promoter region that is responsible for human GLUTl expression has to be 
characterized. Since the rat GLUTl promoter and other glucose transporter promoters 
like GLUT2 (Cha et al., 2002) and GLUT4 (Liu et al., 1992; Olson and Pessin, 1995)， 
have already been characterized, similar strategy was adapted to study the GLUTl 
promoter. This study will focus on the characterization of promoter sequence required 
for the expression of GLUTl gene. 
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4.1 Materials 
4.1.1 Construction of GLUTl Promoter Vectors 
The pGL3-basic and pRL luciferase reporter vectors were kind gifts from Prof. 
L. K. Leung, Department of Biochemistry, The Chinese University of Hong Kong. The 
pGL3-Basic vector lacks the eukaryotic promoter and enhancer sequences, allowing 
maximum flexibility in cloning putative regulatory sequences. pRL vector belongs to a 
family of wild type Renilla luciferase control reporter vector, which provide constitutive 
expression of Renilla luciferase. When cotransfecting both the pGL3-basic and pRL 
luciferase reporter vectors in mammalian cells, the expression of Renilla luciferase 
provides an internal control to which expression of the experimental firefly luciferase 
reporter gene may be normalized. 
4.1.1.1 Restriction Enzymes and Reaction Buffer 
4.1.1.1.1 Restriction Enzymes 
Sad and Xho\ were purchased from New England Biolabs Inc. (Beverly, MA, 
USA). 
4.1.1.1.2 Reaction Buffer 
The reaction buffer New England Biolabs Inc. (Beverly, MA, USA) was 
supplied as a lOX solution containing 10 mM Bis Tris Propane-HCl, 10 mM MgCb, 
ImM DTT, supplemented with 100 |Lig/ml BSA. It was stored at -2()°C until use. 
4.1.1.2 T4 DNA Ligase 
Ligation reaction was carried out using T4 DNA ligase purchased from 
Fermentus (Hanover, MD, USA). 
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4.1.1.3 Bacterial Culture Medium 
The medium used was mentioned in Section 3.1.1.3.1. 
4.1.1.4 Ampicillin Sodium Salt 
A stock solution (25 mg/ml) of ampicillin sodium salt (Amersham, GC 
Healthcare, Buckinghamshire, England) was prepared in double distilled water. The 
working solution (25 jig/ml) was prepared by diluting the stock solution 1000 fold in 
LB medium or LB agar before each single use. The stock solution was stored at -20°C. 
4.1.1.5 Plasmid Purification Kit 
Plasmids were purified as described in Section 3.1.1.4. 
4.1.1.6 Primer Pairs 
The oligonucleotide primers were designed on the basis of the GLUTl genomic 
sequence published in the webpage of Ensembl Genome Browser. The primer pairs 
were synthesized by Invitrogen Life Technologies (Carlsbad, California, USA) and 
were handled in the same way mentioned in Section 2.1.6.2. 
4.1.2 Cell Lines 
All cell lines were purchased from the American Type Culture Collection 
(ATCC, USA). 
4.1.2.1 WRL 68 
WRL68 (ATCC CL-48) is a human embryonic liver cell line that was submitted 
to ATCC in 1969. 
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4.1.2.2 293 
293 (ATCC CRL-1573) is a human embryonic kidney cell line. It serves as a 
transfection host. 
4.1.2.3 HepG2 
HepG2 (ATCC HB-8065) is a human hepatocellular carcinoma cell line 
obtained from a Caucasian adolescent male. 
4.1.2.4 U-87 MG 
U87-MG (ATCC HTB-14) is one of a number of cell lines derived from 
malignant gliomas by J. Ponten and associates from 1966 to 1969 (Ponten and 
Macintyre, 1968). The cells were obtained from a Caucasian 44-year old female. 
4.1.3 Cell Culture Media and Other Reagents 
4.1.3.1 Dulbecco's Modified Eagle's Medium (D-MED), Powder (High Glucose) 
The preparation of high glucose D-MEM was described in Section 3.1.3.1.1. 
4.1.3.2 Poly-D-Lysinc 
It was purchased from Sigma (St. Louis, MO, USA). 
4.1.4 Dual Luciferase Reporter Assay System 
The assay system was purchased from Promega (Madison, WI, USA). The 
reagents were prepared following the manufacturer's instruction. The system provides 
an efficient means to perform two reporter assays. In this assay, the activities of firefly 
and ReniUa luciferases are measured sequentially from a single Sample. The firefly 
luciferase reporter is measured first by adding Luciferase Assay Reagent II (LAR II) to 
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generate a stabilized luminescent signal. After quantifying the firefly luminescence, 
this reaction is quenched, and the Renilla luciferase reaction is initiated by 




Alignment of genomic DNA sequences among the human, rat and mouse 
GLUTl genes was performed by Genomatrix (http://www.genomatix.de/). The 
promoter was predicted by using online softwares: Promoter Scan version 1.7 
(http://thr.cit.nih.gov/molbio/proscan/), which detects the RNA polymerase II promoters 
(Prestridge, 1995)，and WebGene (http://www.itb.cnr.it/sun/webgene/), which predicts 
CpG islands. 
4.2.2 Cell Culture 
The WRL68, 293，HepG2 and U87-MG cell lines were maintained and 
subcultured in high glucose D-MEM as described in Section 3.2.1. 
4.2.3 Construction of GLUTl Promoter Vectors 
4.2.3.1 Amplification of GLUTl Genomic DNA 
In order to identify the minimal promoter for the GLUTl gene expression a -
2726 DNA sequence 5'-upstream from the start of exon 1 served as a reference template 
for the 5'-deletion analysis in this study (Fig. 4.2.1). 
+ i r> 
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Figure 4.2.1 5，-upstream region of the human GLUTl gene. +1 denotes the 
transcription start site of the gene and the regulatory elements reported previously were 
in blue boxes. Enhancerl of the gene located at about -3.6 kb upstream of exon 1. 
The -2726 fragment of human GLUTl genomic DNA sequence was amplified 
using human genomic DNA (Promega, Madison, WI, USA) as template. Two primers 
were designed to perform PCR for the amplification of GLUTl promoter as well as to 
introduce SacHXhol c(oning sites. The 2 primer sequences are as follows: 
Primer 1 (Forward): 
5' A AT GAG CTC GCT CTC TCT ACT CAC TCT CCT TC 3’ 
Sad site 
Primer 2 (Reverse): 
5, A AT CTC GAG GAC TAG CGA CCG GCA CGC TCG 3' 
Xhol site 
PCR reactions were performed in a 50 of reaction mixture containing 0.25 \x\ 
of human genomic DNA equivalent to 46 ng, 5 |al of lOX reaction buffer, 0.4 \i\ of 40 
mM dNTP mix, 1 unit of Pfu DNA polymerase, 1 of 10 mM of both primer 1 and 
primer 2 by the Mastercycler gradient (Eppendorf). The amplification temperature were 
95°C for 5 minutes, 35 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C 
for 6 minutes. After 35 cycles, a final extension was done for 10 minutes at 11�C. The 
-2726 GLUTl promoter PCR product was fractioned by 1% agarose gel. 
4.2.3.2 Gel Purification 
PCR product with the correct molecular size was excised and subjected to gel 
purification using Gel-M™ Gel Extraction System (Viogene, Oberhausbergen, France) 
as described previously in Section 2.2.1.4. 
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4.2.3.3 Restriction Digestion 
Forty nanograms of pGL3-basic vector and 120 ng of purified GLUTl promoter 
DNA fragment were digested by 10 units of Sad and 10 units of Xhol for 4 hours at 
37°C. After digestion the products were separated by 1% agarose gel and purified using 
Gel-M™ Gel Extraction System. 
4.2.3.4 Ligation 
Both the digested pGL3-basic vector and the digested GLUTl promoter DNA 
fragment were subjected to ligation using T4 ligase. The 20 |LI1 of ligation reaction 
mixture containing lOX reaction buffer, 5 units of T4 ligase, insert and vector (molar 
ratio 3:1) was incubated at 16°C overnight to generate the GLUTl promoter-Luciferase 
construct (Fig. 4.2.2). 
Syntholc poly(A) signal I Amp' tianscfipllonal pause sile X �”\\(l��background roductlon) 
/ j / P Sad 
_8bp) r ^ T ^ ^ fragment / / \ ^ - Xho\ ^ \ / / Wco 186 • 
SV40 lalo poly<A) signal \ (lor /UC+ ropoflor) / 
HPS I 1902 
Xba\ 1742 
Figure 4.2.2 Cloning of the human GLUTl promoter region into pGL3-Basic 
vector. Map of the luciferase vector pGL3-Basic. The amplified PCR product was 
cloned into the multiple cloning site region of the vector. Forward primer with 
restriction site Sad and reverse primer with restriction site Xhol were used to amplify 
human GLUTl promoter region 
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4.2.3.5 Transformation 
The resultant ligated plasmid was transformed into E. coli DH5a strain by 
transient period of heat shock as described in Section 3.2.2.1. The transformed bacteria 
were spread onto LB agar plate with 25 |ag/ml of ampicillin and incubated at 37°C oven 
for 16-18 hours. Single bacterial colony was picked and grew in selective LB broth 
containing 25 |ig/ml of ampicillin, for another 16-18 hours for plasmid. 
4.2.3.6 Purification of Plasmid DNA 
Plasmids were purified from bacteria using Wizard® Plus SV Minipreps DNA 
Purification System (Promega, Madison, WI, USA) following the manufacturer's 
instruction as described in Section 3.2.2.2. The plasmids were subjected to sequencing 
analysis by Macrogen Inc. (Seoul, Korea) to ensure that no mutation occurred when 
compared with the published GLUTl genomic DNA sequence in Ensembl Genome 
Browser. 
4.2.4 5'-Deletion Analysis of GLUTl Promoter 
4.2.4.1 Amplification of GLUTl Promoter Fragments of Various Lengths 
Six GLUTl promoter fragments were generated from the -2726 GLUTl 
promoter construct by PCR. For each construct, 72 ng of double-straned -2726 GLUTl 
promoter construct was subjected to PCR amplification by Pfu DNA polymerase. 
Primer pairs used are shown in Table 4.2.1. The components in the PCR reaction are 
shown in Table 4.2.2. The plasmid was initially denatured for 30 minutes at 95°C, 
followed by 35 cycles of 95°C denaturation for 30 seconds, 30-second of annealing at 
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the 60°C and extension at 72°C for 1 to 5 minutes, depending on the size of the 
promoter fragments, a final extension was done at 72°C for 10 minutes. After PCR 
amplification the products were fractioned by 1% agarose gel and the produces were 
then processed as described in Section 2.2.1.4. 
Table 4.2.1 Primer sequences for different promoter fragments 
Promoter Primer set 
Fragment 
-262 Forward: 
fragment 5'-GCA TTG AGC TCG GTA CCG GCT CCA CCA TTT TG-3' 
Sad site 
-787 Forward: 
fragment 5，-GCG CTG AGC TCT GTC CTT AAT GTC CTA TCA TG-3, 
Sad site 
-1187 Forward: 
fragment 5'-GAT ATG AGC TCA CAG CCT CGG CCG GGC TCA GT-3' 
Sad site 
-1587 Forward: 
fragment 5'-GCT ATG AGC TCA CAG ACA GTA AGC CCA CCA TG-3' 
Sad site 
-1987 Forward: 
fragment 5'-GCT CTGAGCTCC ATG AAG AAG GAC CGT GAT GG-3’ 
Sad site 
-2387 Forward: 
fragment 5’-CGC GCG AGC TCC AAA AGG TAC TTA AGG AAA GA-3' 
Sad site 
All Reverse: 
fragments 5 ’ AAT CTC GAG GAC TAG CGA CCG GC A CGC TCG 3' 
Xhol site 
Table 4.2.2 Components in the PCR amplification of various length of GLUTl 
promoter 
Component Volume (|il) 
lOX PCR reaction buffer 5 
10 |LIM primer F 1 
10 i^ M primer R 1 
dNTP mix 0.4 
-2726 GLUTl promoter construct 0.82 
Autoclaved H2O 40.78 
Pfu DNA polymerase 1 
Total: 50 
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4.2.5 Determination of the Activities of GLUTl Promoter Fragments 
4.2.5.1 Transfection 
Four cell lines (WRL68, 293, HepG2 and U87-MG) were used to perform the 
luciferase assay. The seven GLUTl promoter constructs and the control pGL3-basic 
vector were transiently transfected into the cell lines for the determination of promoter 
activity by luciferasf^ assay. pRL vector was also cotransfected with the promoter 
vectors as an internal control. Transfection was performed with Lipofectamine™ 2000 
kit following the manufacturer's instruction. Briefly, 2 x 1O�cells/well were seeded in 
24-well plate overnight (for 293 cell line the plate was first coated with 200 |LI1 of poly-
D-lysine per well to enhance cell adhere). For each well of transfection, 0.8 |ag of 
promoter construct and 1 ng of pRL vector together with 1.6 of Lipofectamine™ 
2000 reagent were diluted by 50 |LI1 of high glucose D-MEM separately and mixed 
gently. After 5 minutes of incubation at room temperature, the diluted plasmids and 
Lipofectamine™ 2000 were then mixed immediately and incubated for another 20 
minutes at room temperature. Thereafter, growth media in the 24-well plates were 
aspirated and replaced with 250 of D-MEM per well together with 100 |LI1 of 
LipofectamineTM 2000-DNA complex. After incubation for 5 hours at 37°C, the 
LipofectamineTM 2000-DNA complex was removed and cells were cultured with fresh 
growth medium. The cells were then allowed to grow for 24 hours at 37°C incubator 
before harvesting. 
4.2.5.2 Dual Luciferase Reporter Assay 
After 24 houis of incubation the cells were then lysed using the IX Passive 
Lysis Buffer (PLB) diluted from a 5X stock (supplied by the kit) with IX PBS. To each 
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well 100 |LI1 of IX P3S was added then the plate was shaken for 10 minutes at room 
temperature to ensure all cells were lysed and detached from the wells. The lysate was 
then transferred to a 1.5 ml microcentrifuge tube and subjected to centrifugation at 
16000 X g at 4°C for 5 minutes to get rid of the cell debris. Twenty microliters of lysate 
was transferred to a luminometer tube and mixed with 50 |LII of LAR II and the 
oxidation of beetle luciferin in LAR II catalyzed by firefly luciferase resulted in photon 
emission and was measured by the luminometer (LUMAT LB 9501, EG&G Hong 
Kong Ltd., Hong Kong). After the measurement, the reaction was quenched by adding 
50 1^1 of Stop & GIG reagent to the same tube and complete activation of the Renilla 
luciferase was also achieve upon the addition of the reagent. The oxidation of 
coelenterate-luciferine to choelenteramide catalyzed by Renilla luciferase result in 
photon emission was measured. 
4.2.5.3 Determination of Transfection Efficiency of Different Constructs 
Cells were seeded and transfected as described in Section 4.2.5.1. After one-day 
incubation cells were harvested in a 1.5 ml microcentrifuge tube and washed twice 
using IX PBS at 201 x g for 3 minutes at room temperature. Then for each 1 x 10^ cells 
400 fxl of lysis buffer was added, and mixed using vortex until no cell debris was seen. 
After that to each tube 20 fxl of protease K (10 mg/ml) was added and incubated at 37°C 
overnight. After the incubation 700 fxl of saturated NaCl was added to each tube 
followed by centrifuging at 16000 x g for 10 minutes at 4°C. The supernatant was 
transferred to another 1.5 ml microcentrifuge tube and 1 ml of ice-cold absolute ethanol 
was added to precipitate the DNA. Thereafter the mixture was centrifuged at 16000 x g 
for 20 minutes at 4°C, after removing the supernatant the DNA pellet was again washed 
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with 1 ml of ice-cold 70% ethanol at 16000 x g for 20 minutes at 4°C. After 
centrifugation, the ethanol was then removed and the DNA pellet was allowed to dry at 
40°C for 30 minutes to remove any residual ethanol. Then 20 fxl of TE buffer 
containing 20 [xg/^ il of RNAase was added to re-suspend the DNA pellet. 
The extracted plasmid DNA was then used as template for PCR amplification, 
both luciferase and GAPDH gene were amplified. PCR was performed in a 25 |il of 
reaction mixture containing 0.2 of extracted DNA, 2.5 |LI1 of lOX reaction buffer, 0.4 
)al of 40 mM dNTP mix, 1 unit of Tag DNA polymerase, 0.5 \i\ of 10 |.iM of both 
forward and reverse primers (Table 4.2.3) by the Mastercycler gradient (Eppendorf, 
Hamburg, Germany). 
The amplification temperatures were 95°C for 5 minutes, 95°C for 30 seconds 
corresponding annealing temperature for 45 seconds, and 72°C for 100 seconds. After 
32 cycles, a final extension was done at 72°C for 10 minutes. The amplification 
products were visualized by EtBr staining 1% agarose gels. 
Table 4.2.3 Primer pairs used in the investigation of transfection efficiency of the 
different promoter constructs 
Annealing 
Gene Primer set temperature Size 
(�C) (bp) 
Forward: 
Luciferase 5'-AAC AGC GAG CGT GCC GGT CGC TAG A-3' 57.0 1652 
Reverse: 
5，-TAA G G C G G G C A G G A G T C T GCG C C T T-3 , 
Forward: 
GAPDH 5'-TAG GGC AAG CTT CTG AAG TGT ACC CGG 55.0 450 
AAAAGG-3' 
Reverse: 




All experiments were repeated at least three times with similar results obtained. 
The presented results represent the pooled values of three to four experiments, each in 
triplicate setup. Each data point is expressed as mean ± S. E. (standard error) unless 




4.3.1 Determination of the Promoter Activity of the 5，-deletion Fragments 
Six GLUTl promoter deletions were generated from the -2726 template and 
subcloned into the pGL3-Basic luciferase vector (Fig 4.3.1). The sequences of the 
fragments were confirmed by DNA sequencing analysis. 
SacI Xhol 
-2726 I I : 
-2387 I I : 
-1987 I 
-1587 I 
-1187 I ~ 
-787 I 丨"c “ 
- 2 6 2 I 
Figure 4.3.1 Seven clones of various S'-deletion of GLUTl promoter. The -2726 
fragment served as the template for 5'-deletion analysis and the promoter activities of 
clones were determined in terms of luciferase (Luc) activities. 
The pGL3-Basic vector alone did not possess any promoter activity, which is 
ideal for testing the hJtivity of the target promoter. The cloned promoter regions both 
the longest and shortest fragments are proven active as compared to that of the vector 
control (Fig 4.3.2). Result shown was obtained from 293 cell line, similar results were 
also obtained in the other three cell lines. 
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Figure 4.3.2 High promoter activities of the cloned GLUTl promoter fragments 
compared to the vector control. Each data point represents the average of three 
separated experiments in triplicates and presented as mean 土 S.E. * Significant 
difference between the pGL3-Basic vector and the promoter inserted vectors. 
Glutl protein :s expressed in many different human tissues and is responsible for 
the basal glucose uptake in the tissues. Four cell lines of different origins were used to 
determine the activities of the promoter constructs. The 293 cell line, which is a human 
embryonic kidney cell line, was used in the present study because GLUTl mRNA was 
found to express in significant amount in the kidney, which facilitates the entry of 
glucose in order to satisfy energy requirements in nephrons (Chin et al., 1993). On the 
other hand, Glutl expression is very low in normal liver tissues, and WRL 68 is a 
human embryonic liver cell line. This expression difference is revealed in the absolute 
value of fir&fly/Renilla ratio, the values from 293 was doubled that of WRL 68 (Table 
4.3.1). Surprisingly, both the relatively high-expresser cell line and low-expresser cell 
line of GLUTl shared a similar result in the 5'-deletion analysis (Fig. 4.3.4). In both 
cell lines the shortest DNA sequence i.e. -262 fragment was the most active, and the 
longest sequence i.e. -2726 fragment was the least active. 
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Although the luiferase assay results observed in the liver cancer cells, HepG2 
were similar to that of the 293 and WRL 68 cells. The absolute values of relative 
firefly/Renilla ratio was about 4-fold higher than that of WRL 68 and doubled of the 
293 cells (Table 4.3.1). The oncogenes in HepG2 cells might be partly responsible for 
the high activity of the GLUTl promoter, resulting in the high Glutl expression level in 
the cell line. The values of U-87 MG cells were unexpectedly low this was suspected 
due to the low transfection efficiency, but the amplification of luciferase gene in the 
luciferase vectors extracted from the cell lysates showed similar transfection efficiency 
of different promoter fragments, which eliminate this possibility (Fig. 4.3.3). The low 
luciferase activity may be a result of low activity of the GLUTl promoter instead of low 
transfection efficiency. 
Table 4.3.1 Firefly/Renilla relative luciferase activities of 4 cell lines. The activities 
of firefly luciferase were divided by the activity of Renilla luciferase to normalize the 
transfection efficiency. Each data point was the average of three separated experiments 
in triplicates and presented as mean 土 S.E. 
“ Ce I line — 
GLUTl promoter WRL 68 HepG2 U-87 MG fragment 
-262 0.186 ±0.023 ~57ll7± 0.006 “ 0.513 ±0.045 0.029 ± 0.004 
“ -787 0.173 ±0.019 ~57089 ± 0.014 0.287 ± 0.024 0.019 ± 0.002 
-1187 0.155 ±0.010 0.089 ±0.011 0.265 ± 0.013 ± 0.003 
~ -1587 0.154 ±0.023 0.077 ± 0.010 0.311 ±0.037 1 . 0 1 4 ± 0.002 
-1987 0.133 ±0.023 0.077 ± 0.008 _ 0.304 ± 0.025 0.017 ±0.002 
“ -2387 0.144 ±0.031 ""57076 ± 0.010 ““ 0.242 ± 0.021 0.014 ± 0.001 
“ -2726 I 0.092 ± 0.015 I 0.059 ± 0.006 I 0.177 ±0.020 | 0.012 ± O.OOT" 
116 
1 2 3 4 5 6 7 8 M 
(1652 bp) 
GAPDH i m m m o ^ s n 
(450 bp) • • • • • • l ^ ^ l 
Figure 4.3.3 Transfection efficiency of promoter constructs of different sizes in U-
87 MG cells. The luciferase gene was amplified using the extracted plasmid DNA as 
template. Upper panel: lane 1) pGL3-basic control, 2) -262 fragment, 3) -787 fragment, 
4) -1187 fragment, 5) -1587 fragment, 6) -1987 fragment, 7) -2387 fragment, 8) -2726 
fragment, M) 1 kb marker. Lower panel: GAPDH gene amplified serving as a loading 
control for the experiment. 
The U-87 MG cell line, which is a human glioma cell line was used in the study 
to examine the activities of the luciferase constructs as it is a cell type that is more 
related to the cells found in the blood brain barrier which is believed to contribute to 
GlutlDS. However due to the low activity of the GLUTl promoter in the cell line, its 
results from luciferase assay were inconclusive (data not shown). 
According to the results among the three cell lines: 293, WRL 68 and HepG2 
cells, the shortest fragment showed the highest luciferase activity, while the longest 
fragment exhibited the lowest activity among all fragments tested (Fig. 4.3.4). 
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Figure 4.3.4 Luciferase activities of GLUTl promoter constructs carrying different 
human GLUTl 5'-flanking DNA sequence. Luciferase activities were measured 24-
hour after transfection and the activities of the constructs were calculated as the 
percentage of the -262 construct after normalizing the transfection efficiency with the 
Renilla luciferase activity. Luciferase activities A) in 293，B) in WRL 68，and C) in 
HepG2. Each data point represents the mean 士 S.E. of 3 individual experiments in 
triplicates. *,# Significant difference compared to either -262 or -2764 fragment as 
indicated. 
4.3.2 Prediction of Transcription Factors in the 5，-deletion Fragments 
Among all three cell lines, there were significant differences between -2726 
fragment and the fragments: -262，-787，-1187，and -1587. The luciferase activity 
decreased from -1587 to -2726 fragment. A repressor element is therefore suspected to 
locate in between -1587 to -2726 fragment. Among the list of transcription factors 
predicted by the online transcription factors prediction tool, TESS, 2 potential 
transcription factors, RAR-beta and SRF were predicted (Table 4.3.2). Another 
potential repressor, GCF was predicted in between -262 and -787 fragment (Table 
4.3.2)，which might account for the initial drop in luciferase activity particularly 
significant in the HepG2 cells. 
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Table 4.3.2 Human transcription factors predicted to interact with the human 
GLUTl promoter 
Transcription Sequence Function 
factors 
(location) 
Oct-1 TACTTTgCAT Purified octamer binding transcription 
(_515) factors stimulate RNA polymerase Ill-
mediated transcription of the 7SK RNA 
(Murphy et al., 1989) 
Freac-6 tAAAYAAAYANNM The winged helix transcriptional activator 
(HFH3) HFH-3 is expressed in the distal tubules of 
(_528) embryonic and adult kidney (Overdier et al., 
19^ 
GGGTGGAGtCAGG Enhancer binding factors AP-4 and AP-1 act 
in concert to activate SV40 late transcription 
in vitro (Mermod et al； 1988) 
QC F C C G G C C G Molecular Cloning and Characterization of a 
(-627) Human DNA binding factor that represses 
transcription (Kageyama and Pastan, 1989) 
RAR-beta GAGGTCaGGG Negative regulation of AP-1 responsive 
(_1813) genes (Schiile et aL, 1991) 
c-Ets-1 AGGAGGATGtG Sequence-specific binding of human Ets-1 to 
(-1814) the T cell receptor alpha gene enhancer (Ho 
et al., 1990) ‘ 
H4TF-2 GGoGAGGaCT Distinct transcription factors bind 
(-2052) specifically to two regions of the human 
histone H4 promoter. (Dailey et al., 1986) 
"ATF TGAGGTCaGGG The Adenovirus EIIA Enhancer (Loeken et 
(-2059) al., 1989) 
AP-4 CCGCAgCTGG Enhancer binding factors AP-4 and AP-1 act 
(-2440) in concert to activate SV40 late transcription 
in vitro (Mermod et aL, 1988) 
SRF CCAaAGAAGG Repression of c-fos transcription is mediated 
(-2500) through p67SRF bound to the SRE (Shaw et al., 1989) 
E12 GcCACATGTC A new transcriptional-activation motif 
(-2543) restricted to a class of helix-loop-helix 
proteins is functionally conserved in both 
yeast and mammalian cells (Quong et aL, 
1993) 
Key: Y= T or C; M= A or C; N= any nucleotide 
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4.4 Discussion 
The alignment among the sequences of human, mouse and rat GLUTl gene 
showed a relatively low homology in the 5,-upstream region however there are still 
some conserved segments in the 5'-upstream region (Fig. 4.4.1). A -2726 fragment of 
human GLUTl was chosen for my thesis study because two enhancers were reported to 
locate at around -2.7 kb and -6.6 kb upstream of exon 1 in mouse GLUTl gene 
(Murakami et al., 1992) and putative enhancers were predicted at similar regions in 
human GLUTl gene (Ng et al., 2002). We are interested to investigate if there are any 
other enhancers or repressors downstream of these putative enhancers. Also, this -2726 
segment covers 13 single nucleotide polymorphisms (SNPs), some of them are 
positioned closely to the conserved segments (Fig. 4.4.1) and others like the one found 
to be associated with clear-cell renal carcinoma at -1513 (Page et al., 2005), though 
was not located in the conserved region, still it is an important SNP. Therefore, this -
2726 segment might be useful for SNP study in the future. In this study seven 
luciferase reporter gtne constructs of the GLUTl promoter with various length of 5'-
flanking sequence were generated using the -2726 fragment as the template. 
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Based on the results of the luciferase assays obtained from 293, WRL68 and 
HepG2 cell lines, a promoter activity trend was seen: the shortest fragment (-262) was 
more active than the longest fragment (-2726), implicating one or more negative 
regulatory elements are present in this promoter region. It is believed that the minimal 
functional promoter for GLUTl gene expression is located within the -262 fragment. 
Predictions using online softwares also showed that the -262 fragment contained a 
potential promoter based on the presence of CpG island and the putative eukaryotic 
polymerase II promoter sequences (Prestridge, 1995), both are the characteristics of 
promoter region and putative eukaryotic polymerase II promoters. 
The luciferase activity in normal cell lines showed a gradual decrease among the 
series 5,-deletion fragments and the luciferase activity of the -2726 fragment was about 
half that of the -262 fragment, while in the HepG2 cancer cell line, a significant 
decrease of activity was observed in between -262 fragment and -787 fragment and the 
activity of the -2726 fragment was only 60% that of the -262 fragment (Fig. 4.3.4). The 
basal expression varied significantly among the cell lines. This might be partly due to 
the presence of oncogenes and also a result of the relative effect of some putative 
negative elements in different cell lines. By using the online transcription prediction 
tool, TESS, a potential repressor was found in the -262 to -787 region (Table 4.3.2). 
GCF (GC factor), binds to GC-rich sequences (Kageyama and Pastan，1989), which is 
often recognized by Spl (Dynan and Tjian，1985). In between the -262 and -787 
fragment there is a GC-rich region, which might be the potential binding site of GCF. 
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GCF was found to repress the expression originating from p-actin and calcium-
dependent protease promoters (Kageyama and Pastan et al., 1989). 
In between tl e -1587 and -2726 fragments, two potential transcription factors 
were predicted: SRF and RAR-beta (Table 4.3.2), both are related to cell growth, 
development and differentiation (Strickland and Mahdavi, 1978; Wang et ai, 1985; 
Hauguel-de Mouzon et al., 1994). It has been reported that the transcription of human 
proto-oncogene c-fos is repressed by the binding of to the serum response 
element (SRE) (Treisman, 1986). In mouse fibroblast cell line c-fos was found to be a 
crucial factor for the up-regulation of GLUTl expression upon serum induction 
(Santalucia et al., 2003). Upon the binding of SRF to the SRE in GLUTl promoter 
region, repression of GLUTl expression, together with the repression of c-fos by the 
same factor may occur and consequently results in the low expression of the GLUTl 
gene. If the binding of SRF is confirmed this will be the second SRF binding site on the 
human GLUTl in addition to the one predicted in enhancer-1 (Murakami et al., 1992; 
Ng et al., 2002). The other predicted transcription factor, RAR-beta belongs to the 
retinoic acid receptor (RAR) subfamily, which is a member of the steroid receptor 
superfamily (Evans, 1988; Mangelsdorf et al., 1990). It has been shown to repress 
transcription of the human collagenase gene and stromelysin gene (Brinckerhoff et al, 
1986; Nicholson et c /., 1990; Sirum and Brinckerhoff, 1989). It was found that RAR-
beta did not interact with DNA sequence directly instead, it might inhibit the binding of 
other factors (e.g. AP-1) to the DNA sequence or block/ destabilize the protein-protein 
interaction between other transcription factors, hence, results in repression of genes 
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expression (Schiile et al., 1991). An SNP is positioned at the binding site of this 
predicted transcription factor. It will be interesting to investigate whether the SNP 
affects GLUTl expression by changing the binding of transcription factor. 
Among the three cell lines studies, the luciferase activities were repressed to 
varied levels as the promoter length increases. Both positive and negative regulatory 
factors can interact with the same DNA sequence. The combination of the positive and 
negative regulators may be cell type-specific, hence, resulting in different levels of 
repression in different cell types. Resolving the sequences that mediate basal 
transcription, cell type differences and confirmation of the presence of negative 
regulatory elements require further experimentation that are beyond the scope of this 
thesis. 
In using the online transcription factor prediction tools, there is a risk of 
underestimating the number of transcription factors interacting with a target sequence. 
Since the prediction is based on the database of the software, only the known factors in 
the database can be scanned, further experiments have to be performed to verify the 
predicted interactions. 
The firefly/Ren ilia relative luciferase activities were the highest in HepG2 cells 
(Fig 4.3.2)，which is probably partly due to the presence of oncogene expression in the 
cells. Normally, GLOTl shows minimal expression in Kupffer cells in liver and cells 
localized in the hepatic endothelium (Spolarics et al., 1993). However, malignant cells 
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have accelerated me! ibolism and increased requirements for ATP production. Early 
studies conducted by Salter et al. (1982) and Hatanaku and Hanafusa (1970) showed 
that the Rous sarcoma virus transformed cells exhibited increased glucose uptake by 
Glutl protein. Oncogenes were found to be responsible for the up-regulation of GLUTl 
expression. Oncogenes including: src, ms, myc and abl have been reported to increase 
GLUTl mRNA in vitro (McGowan et al., 1995). 
It has been shown that the level of Glutl protein was positively related to the 
invasive potential of cancer cells (Grover-McKay et al., 1998) and Glutl expression in 
tumor also correlated with the survival of patients (Baer et al., 1997; Haber et al 1998; 
Cantuaria et al., 2001). In order to combat cancers, scientists have been trying to 
modulate the activity of Glutl protein by using inhibitors and also attempt to down-
regulate the expression of the GLUTl gene. 
In contrast to the case of cancers, enhancing GLUTl gene expression has been a 
strategy of treating ClutlDS but with little success in spite of the positive effects in in 
vitro studies (Kulikova-Schupak et aL, 2001). It is important to identify the factors that 
regulate the expression of GLUTl gene in order to alter the gene expression in a way 
that will benefit the GlutlDS patients. The understanding of the regulation of the 
GLUTl gene will facilitate the development of agents usable for treating GlutlDS or 
even cancers. 
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In this study ihree cell lines were tested and in general they showed similar 
results. However, some researchers suggested that transfecting model culture cell lines 
with promoter-reporlf^r constructs may not reflect the real activity of the promoter (Liu 
et al., 1992) because the DNA regions that are crucial for promoter function in vivo may 
not always be evident in transient transfection assays performed in cultured cell lines 
(Pinkert et al., 1987; Ross et al” 1990). In theory, it would be better to start from a 
farther 5'-upstream region in order not to miss some major distal regulatory elements. 
An alternative will be using transgenic mice in which the promoter-reporter constructs 
are injected into the pronucleus of fertilized mouse embryos. 
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Chapter 5 
General Conclusion and Future Perspectives 
In this thesis, a novel insertion mutation, 1034-1035Insl2, was identified in the 
GlutlDS patient. The results supported the hypothesis that GlutlDS is a consequence 
of a loss of function mutation that changes amino acid sequences of the Glutl protein. 
The 1034-1035Insl2 mutation, which predicted to encode four extra amino acid 
residues, cause a efflux reduction in the patient's erythrocytes and expression of this 
mutant Glutl in CHO-Kl cells resulted in impaired 2-DOG uptake activity. In Chapter 
4, all the 5'-deletion fragments of the GLUTl promoter were active in the tested cell 
lines (293，WRL 68 and HepG2). Among the three cell lines, the shortest fragment -
262 is the most active whereas, the longest fragment -2762 is the least active. Also, 
potential transcriptioi. factors (RAR-beta, SRF and GCF) were found in the promoter 
region. Through the determination of luciferase activity difference, from the co-
transfection of the potential transcription factors and the GLUTl promoter vectors, the 
interaction of the predicted transcription factors and GLUTl promoter sequences may 
be verified. 
Through studying the mutations found in the GlutlDS patients, our knowledge 
on the effects of genetic variations on Glutl expression and function has been advanced. 
Such knowledge promotes the understanding of the Glutl structure-function 
relationship in spite of the lacking of the protein crystals. In concerning the promoter 
region, the present study predicted potential regulatory elements in the GLUTl 
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promoter region. Understanding of transcription regulation of the GLUTl promoter 
region enables the development of therapeutic strategies targeting to the promoter. 
Phenytoin has been shown to up-regulate the expression of GLUTl mRNA (Wong et 
al., 2005) and improve the clinical state of GlutlDS patients. These evidence support 
the idea that the GLUTl promoter is a possible target for GlutlDS therapy and likely 
other Glutl-associated diseases e.g. cancers. 
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